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CHAPTER 1 INTRODUCTION
1.1 Cancer as a Disease
Cancer is a group of diseases characterized by uncontrolled cell
proliferation, resistance to cell death, evasion of immune system destruction,
angiogenesis, invasion as well as metastasis1,2. Various genetic mutations in
oncogenes or tumor suppressor genes together with many epigenetic factors such
as changes in DNA methylation are considered as contributors to the disruption of
cell signaling, cell growth, and cell proliferation control, which leads to
tumorigenesis and cancer development3–7.
Cancer is considered as a serious killer. According to the world health
organization (WHO) 8.2 million individuals died from cancer in 2012 and the
number of new cancer patients is expected to increase by around 70% in the
coming 20 years. In the United States, cancer is the second leading cause of death
just after the cardiovascular diseases as reported by the National Center for Health
Statistics (NCHS) for the year 20148. American Cancer Society estimated that
there will be 1,685,210 new cancer cases and 595,690 cancer deaths, in 2016 in
USA alone9.
Different therapeutic interventions are available to overcome cancer and
increase patient’s survival rates. Among these, surgery and radiation therapy are
the first line therapeutic strategies for cancer, however, for metastatic cancers they
are not effective as standalone therapy. Chemotherapy, on the other hand, is one
of the most commonly used therapeutic strategies to fight both local and metastatic
cancers either alone or as adjuvant therapy10,11. However two major limitations for
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cancer chemotherapeutic drugs are toxicity towards rapidly growing normal cells,
as well as the emergence of multi drug resistance (MDR) mechanisms, leading to
poor therapeutic outcomes1.
1.2 Liver Cancer
Liver cancer is a type of neoplasm that affects the hepatic tissues.
According to WHO, liver cancer was the second most common lethal cancer
worldwide in 201212. In contrast to the declining trend among most cancer types,
liver cancer showed increase in incidence and mortality rates, indicating its poor
prognosis9,13. American cancer society, estimated 39,230 new cases of liver
cancer to occur in the US during 2016, approximately three-fourths of which will
be hepatocellular carcinoma (HCC)14.
1.2.1 Hepatocellular Carcinoma Risk Factors
Hepatocellular carcinoma is the most prevailing histological type of liver
cancer15. It occurs mostly in inflamed and cirrhotic liver, with the most common
causes being the Hepatitis B (HBV) and Hepatitis C (HCV) viral infections 15,16.
Other risk factors correlated with HCC are aflatoxin B1 ingestion, alcohol and
tobacco consumption, non-alcoholic fatty liver disease, iron overload in
hemochromatosis17 and type 2 diabetes18.
1.2.2 Hepatocellular Carcinoma Therapeutic Strategies
There are multiple treatment strategies for HCC depending on liver function,
the tumor size, number of lesions and stage. Surgical liver resection to remove the
tumor with some healthy tissues around it is mostly performed in case of noncirrhotic, single tumor lesion as opposed to the cases of cirrhosis or multiple

3

invasive tumor lesions. The latter cases are more susceptible to post resection
recurrence of tumor19,20. Non-surgical but invasive therapeutic approaches include
percutaneous ethanol injection (PEI)21, radiofrequency ablation (RFA)22, local
radiotherapy (LR) and trans arterial chemoembolization (TACE) 23, that are used
for patients who are not candidates for resection. Liver transplantation is another
therapeutic modality for HCC with limitations of being a big and expensive
procedure. In addition it takes long time to find a well matched liver donor, and
requires immunosuppressive treatment post operation to avoid new liver
rejection19,24. Unfortunately, the majority of HCC patients (>80%) are diagnosed at
an advanced stage where the above curative therapeutic options would not be

effective25,26. Systemic chemotherapies such as cytotoxic drugs or antiangiogenic
agents are mostly the treatment of choice for patients with advanced late stage
HCC, in addition to their application as adjuvant therapies with other treatment
options. Systemic cytotoxic small molecule treatments such as doxorubicin,
epirubicin, cisplatin, 5-fluorouracil, etoposide and their combinations were used for
advanced HCC, however very low efficacy with no more than 20% response rate
was achieved25,26. On the other hand, newer therapies using sorafenib or erlotinib
have demonstrated antiangiogenic activity as a result of being tyrosine kinase
inhibitors. Bevacizumab is antiangiogenic monoclonal antibody against vascular
endothelial growth factor (VEGF). They work by inhibiting the VEGF or EGF
signaling and hence suppress the tumor’s ability to generate new blood
vessels27,28. In terms of cancer chemotherapy, there are several physicochemical
factors such as the molecular weight, stability, and hydrophobicity of drugs as well

4

as pathophysiological and

anatomical factors such as their inefficient

accumulation in tumor tissues, the involvement of various chemo-resistance
mechanisms by cancer cells among others, that contribute to the inefficient
therapeutic outcomes of the HCC systemic chemotherapy28–31.
1.3 Cancer Cells Chemoresistance
Cancer cells are found to have tremendous ability to develop various
resistance mechanisms to chemotherapeutic agents and to upregulate specific
molecular targets and proteins that have essential roles in increasing tumor
growth, invasiveness, and metastasis32,33.
Chemoresistance mechanisms are various and principally include:
Overexpression of P-glycoprotein (Pgp) and multidrug resistance associated
proteins (MRP) that form efflux pumps which export the chemotherapeutic agents
out of the cancer cells and help cells evade their cytotoxic effect 34,35. The
overexpression of growth factors and amplification of survival signals in response
to chemotherapy induced stress, induction of enzymes metabolizing anticancer
drugs, alteration of the drug target proteins so they have less binding affinity to the
drug or alterations in the downstream signaling proteins, and downregulation of
the drugs cellular transporters which decrease their effective concentration in
cancer cells33,36.
As a result, cancer cells no longer respond to chemotherapy, which
consequently leads to treatment failure. Use of anticancer drugs which have
different mechanisms of action in combination, or the use of drugs and
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genes/siRNA combination could be an alternative approach to overcome tumor
cells resistance and restore their therapeutic responsiveness 36,37.
1.4 Nrf2 (nuclear factor erythroid 2-related factor 2) Transcription Factor
Nrf2 is a key transcription factor that has a fundamental role in the cellular
defense against different toxicants, xenobiotics and any internal or external
oxidative insults.
1.4.1 Nrf2 Mechanism of Action
Nrf2 works in the Nrf2- Keap1 (Kelch-like erythroid cell-derived protein1) ARE (antioxidant response element) signaling pathway. Under normal conditions,
the transcription factor Nrf2 binds to its repressor protein Keap1 which marks it for
ubiquitination and subsequent proteasomal degradation38,39. However when cells
are exposed to oxidative stress, the Keap1 protein gets covalently and
conformationally modified in a way that no longer promotes Nrf2 ubiquitination and
degradation with subsequent Nrf2 stabilization and accumulation in the
cytoplasm40,41. The accumulated free Nrf2 in the cytoplasm then translocates to
the nucleus where it dimerizes with Maf (masculoaponeurotic fibrosarcoma)
protein and binds to the AREs in regulatory region of many metabolic, antioxidant
and cytoprotective genes to induce their transcription 42. Among the genes which
Nrf2 promotes their transcription are the genes of : GSH (glutathione) forming and
metabolizing enzymes, antioxidant proteins, reactive oxygen species neutralizing
enzymes, drug metabolizing enzymes, efflux pump multidrug resistance protein 1
(MRP1)43. All these proteins are known to participate in the cellular protection and
detoxification processes.
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1.4.2 Dual Role of Nrf2 in Cancer
There is dual role noted for Nrf2 and it may be considered as a doubleedged sword. While on one hand Nrf2 helps to protect the normal cells from
neoplastic transformation (when exposed to various carcinogens), by reducing the
reactive oxygen species (ROS) burden and by acting against DNA damage in cells,
on the other hand, it promotes the cancer cells survival and increases their chemo
and radio resistance. As a consequence, high levels of Nrf2 in cancer patients
were reported to be an indicator of poor prognosis44,45.
Nrf2 was found to be constitutively elevated and activated in many cancer
types including:

breast46,47, hepatocellular48,49, prostate50, gall bladder51,

oesophageal52, pancreatic53 and non-small-cell lung54 carcinomas. As illustrated
in figure 1.1, Nrf2 promotes cancer cells proliferation and chemoresistance. In
various carcinomas, elevated Nrf2 level promotes cells aggressive proliferation
and anabolism through induction of purine nucleotides (DNA and RNA forming
units) synthesizing enzymes, glutathione (mitosis and cell cycle promotor)
synthesizing enzymes55 as well as glucose metabolizing enzymes expression 56.
Highly activated

Nrf2

contributed

to

resistance

development

to many

chemotherapeutic agents such as doxorubicin, cisplatin, and 5-fluorouracil (5-FU).
Nrf2 mediated chemoresistance mechanisms reported include induction of
expression of genes encoding antioxidant proteins, as well as drug detoxifying
enzymes and increasing drug efflux pumps production 44,45.
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Figure 1.1. Schematic illustration of Nrf2 roles in enhancing cancer cell
proliferation and development of chemoresistance to anticancer chemotherapeutic
drugs.
1.4.3 Nrf2 in Hepatocellular Carcinoma

In addition, Nrf2 was reported to have a proven role in cancer proliferation,
invasion and metastasis in HCC through regulation of Bcl-xL (antiapoptotic protein)
and MMP-9 (matrix metalloproteinases-9, a protein regulating cell migration and
invasion)

expression49.

Literature

suggested

that

Nrf2

is

involved

in

chemoresistance in HCC and its inhibition by sorafenib can sensitize cancer cells
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to 5-FU57. It was also reported that Nrf2 down regulation by miRNA-340 reversed
cisplatin resistance in Hep G2 /cisplatin resistant HCC cells 58. In another study, it
was documented that apigenin resensitized HCC BEL-7402/doxorubicin resistant
cells to doxorubicin via reducing Nrf2 expression 59. These results emphasize the
importance of targeting Nrf2 in fighting HCC. In this study we applied RNA
interference (RNAi) technique, using polymeric micelles loaded with Nrf2 siRNAs
to knockdown Nrf2 gene in Hep G2 hepatocellular carcinoma cell line in which Nrf2
was reported to be mainly distributed in the cytoplasm 60.
1.5 Small Interfering RNA (siRNA) Therapy
RNA interference (RNAi) is an efficient post-transcriptional gene silencing
process. RNAi through small interfering RNA (siRNA) is highly regarded as a
promising therapeutic strategy to inhibit and silence specific genes involved in
pathogenesis of different diseases61–64.
1.5.1 Mechanism of Action
siRNA is small double stranded RNA (21-23 nucleotides) that are able to
target a specific mRNA of complementary sequence. In the cytoplasm, siRNA is
loaded in RNA-induced silencing complex (RISC), where its sense strand
(passenger strand) gets cleaved by the argonaute 2 (AGO 2) protein. The activated
RISC carrying the antisense strand (guide strand) recognizes the complementary
sequence in the target mRNA and mediates its degradation with consequent
mRNA specific gene silencing65–68.
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1.5.2 Systemic Delivery Barriers
Researchers faced multiple challenges during the systemic delivery of
naked siRNAs, which end up with insufficient accumulation in cytosol of target cells
and hence result in poor therapeutic outcomes. These obstacles include:
degradation in serum with the endonucleases after intravenous injection, short
plasma half-life (< 10 minutes) and rapid renal clearance 69, also its very large size
and high negative charge prevents it from diffusion through the anionic cell
membrane readily61,70. As a result, therapeutic application and significant clinical
benefit of siRNA are dictated by the availability of safe, well designed, effective
siRNA carriers or delivery systems70,71.
In this regard, several different nanocarriers have been used and studied
for protecting and delivering siRNA efficiently to the cytoplasm of target cells.
Among these, nanotechnology utility has helped to improve the biological stability
of siRNAs, their pharmacokinetics as well as cellular uptake. Thus far, using such
systems, satisfactory therapeutic outcomes have been obtained 72,73.
1.6 Nanocarriers, Drugs/Genes
Chemotherapy Problems

Delivery

Systems,

As

Solution

to

It is a well-known fact that delivery of siRNAs and drugs to the target organs

and tissues has been a challenge. In terms of delivery strategies, many
nanocarriers including dendrimers, liposomes, polymeric nanoparticles and
polymeric micelles have been extensively studied to achieve either passive or
active targeting of chemotherapeutic agents or siRNA/genes to the tumor
tissues74,75.
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These nanosystems not only accumulate in the cancerous tissue by
exploiting the leaky tumor vasculature or the enhanced permeability and retention
(EPR) effect but can also be internalized into the tumor cells by receptor mediated
uptake76,77. Nanocarriers also protect the drugs/nucleic acids from burst release or
degradation, improve their cargo pharmacokinetics, increase drug solubility, and
reduce toxicity as well as unfavorable side effects thereby enhancing patient
compliance74,75,78. Although several nanocarriers are under development or in the
clinical trials stages, only a few have been approved by the FDA. These
shortcomings necessitate the need to fast-track the development of delivery
technologies, including the more promising and beneficial targeted nanodelivery
systems1,79.
1.6.1 Polymeric Micelles
Polymeric nanomicelles are one class of nanocarriers that are constructed
from amphiphilic block copolymers that can self-assemble in aqueous environment
to form spherical core-shell structures, at concentration above the critical micellar
concentration (CMC)80,81. Amphiphilic copolymers are composed of hydrophilic
and hydrophobic moieties and when CMC is reached the hydrophobic moieties
start to come closer to each other and away from water to reach more favorable
entropy forming the micellar core while the hydrophilic moieties form the micellar
shell82. Different hydrophobic drugs have been loaded in micellar core through their
interaction with the core hydrophobic groups. On the other hand, hydrophilic shell
groups confer water solubility and diminish protein (opsonin) adsorption on
micelles, which consequently improves the micelle’s cargo blood stability and
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circulation half-life83. It is proven that solubility, stability and circulation time of
hydrophobic chemotherapeutic agents are enhanced by their encapsulation in the
micellar core78,82,84. Being water soluble and of nanosize, micelles carrying
hydrophobic anticancer drugs can be administered intravenously to achieve better
drug penetration and passive accumulation in the tumors83,85. Functionalization of
the micellar shell with targeting ligands not only allow their active accumulation
selectively in tumor tissues, but also decrease the chemoresistance to their drug
cargo through evasion of efflux pumps and achieving receptor mediated
endocytosis75,86. Different types of polymeric nanomicelles are illustrated in figure
1.2.
1.6.2 Multifunctional Polymeric Micelles for Cancer Therapy
Multifunctional polymeric micelles as the name suggests, are the ones in
which more than one therapeutic agent, or therapeutic and diagnostic/imaging
agents can be integrated on the same micellar carrier, with or without the
attachment of targeting moieties for selective delivery80. It is well documented that
multifunctional micellar nanocarriers can help achieve synergistic control over
cancer growth by co-delivery of genes/ siRNA and chemotherapeutics at the same
time87–89. Co-delivery of different therapeutic agents that work by different
mechanisms

of

action

is

a

desirable

approach

to

overcome

cancer

chemoresistance and improve therapeutic efficacy90. Theranostic multifunctional
polymeric micelles have been reported to perform both therapeutic and imaging
functions through incorporation of imaging probes as well as therapeutic
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drugs/genes in the micellar constructs91,92. Multifunctional micelles as a result, has
a great potential for application in cancer therapy.

+

+

+

+

+
+
+

Unifunctional
Micelles
+

+

+
+

+

+

+
+
+

+
+
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Figure 1.2. Schematic illustration of different types of polymeric nanomicelles.
1.7 Poly(styrene-co-maleic anhydride partial iso-octyl ester) (SMAPIE)
Copolymer, As a Micellar Core Building Block

In terms of the nanomicellar carrier building polymers, poly(styrene-co-

maleic anhydride partial iso-octyl ester) (SMAPIE) is a partial ester of the wellstudied polystyrene-co-maleic anhydride (SMA) copolymer. It is established that
the hydrophobic styrene groups in SMAPIE copolymer can participate in formation
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of compact micellar core during fabrication of polymeric micellar delivery systems
for efficient encapsulation and delivery of hydrophobic anticancer drugs 93,94. In
terms of the use of SMA for drug delivery applications, the base polymer has been
proven to be safe for in vivo use. Indeed SMA polymer was used in the synthesis
of many polymeric drug conjugates such as fenoprofen-SMA and gemfibrozil-SMA
conjugates95, SMA-neocarzinostatin (also known as SMANCS)96 and SMA
conjugated YIGSR97. The micellar SMA-doxorubicin98 and SMA-pirarubicin 99 also
showed better pharmacokinetic and pharmacodynamic profiles compared to those
of the free drug in animal tumor models.
1.8 Branched Polyethylenimine (PEI) Polymer, As a Micellar Shell Building
Block

Polyethylenimine (PEI) polymer has many hydrophilic amine groups that

can be used to form hydrophilic shell of a micellar system. In addition, PEI is one
of the most efficient cationic polymers used for gene/siRNA delivery both in vitro
and in vivo applications100–102. As a cationic polymer it is relatively safer, less
immunogenic,

simpler to prepare and cheaper than the viral vectors 103. PEI

cationic amine groups can efficiently condense anionic phosphate groups of
nucleic acids via electrostatic interaction and improve their cellular uptake via
endocytosis104. The intrinsic endosomolytic ability of PEI allows the endosomal
escape of the delivery system cargo via the “proton sponge” mechanism and
hence can increase transfection efficiency105. The “proton sponge” effect of the
protonatable amine groups causes the protons and water influx in the endosomes,
which results in the endosomal membrane rupture releasing the drugs/siRNA
cargo into the cytoplasm after evasion of the lysosomal degradation 71. In addition,
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modification of some of the amine groups of PEI with targeting moieties can reduce
its charge density, cytotoxicity and improve its targeting ability104,106. Modification
of PEI with targeting ligands or imaging agents can be efficiently done using copper
free “click” chemistry.
1.9 Copper Free “Click” Chemistry Application in Micellar Surface
Functionalization
Copper free “click” chemistry is a simple, rapid, highly selective, water

compatible, and bioorthogonal chemical approach that involves ligation of two
moieties through strain promoted 1, 3 dipolar azide alkyne cycloaddition 107,108.
Copper free “click” synthetic module is more useful compared to the copper
catalyzed “click” reactions since copper free reactions don’t involve the oxidative
damage and toxicity that could be caused to the cells and tissues due to residual
copper catalyst remaining in the purified product 109. As shown in figure 1.3, the
driving force for the copper free “click”

approach is the strain of alkyne

encountering ring, as in the dibenzyl cyclooctyne (DBCO) ring instead of the
copper catalyst in the copper catalyzed reaction 108. The copper free “click” type
reported by Bertozzi and co-workers is biocompatible and bioorthogonal reaction
that can occur inside the living systems without inducing toxicity or interfering with
native biological molecules or processes 107.
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Copper free reaction
A

B

+

Strained DBCO
containing molecule A

Copper catalyzed reaction

A
Terminal alkyne
containing molecule A

+

A

Azide containing
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B

Azide containing
molecule B

B

Triazole linked conjugate

Cu(I)

A

B

Triazole linked conjugate

Figure 1.3. Schematic illustration of the strain-promoted alkyne-azide
cycloaddition copper free “click” reaction (SPAAC) and the copper-catalyzed
alkyne-azide cycloaddition “click” reaction (CuAAC).

“Click” chemistry has been used in many applications including biorthogonal

imaging or labeling of different biomolecules as proteins or nucleic acids using
alkynyl or azido sugars or amino acids probes110–114, in situ fragment based drug
development with example of multivalent enzyme or receptor inhibitors
construction115,116, synthesis of fluorescently labeled targeted drug nanocarriers
for cancer therapy and imaging117.
In this study we synthesized azide modified modular micellar platform that
can be decorated off-the-shelf with different cyclooctyne linked targeting moieties
or imaging agents simultaneously using the same rapid copper free “click” reaction
to arrive at nanomicelles suitable for theranostic and metastatic cancer therapy
application. Importantly, the concept can be utilized to quickly assemble the
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micellar nanocarriers constructed using off-the-shelf library of the synthesized
azide/alkyne block co-polymers (containing various drug and gene payloads)
decorated with various targeting ligands for treating multiple different cancers that
overexpress several kinds of receptor domains.
1.10 Galactosamine as Efficient Targeting Ligand for Selective HCC Therapy
Galactosamine is among the selective targeting ligands used for targeting
hepatocellular carcinoma due to its high binding affinity to asialoglycoprotein
receptor. Asialoglycoprotein receptors (ASGPRs), also known as (Ashwell
receptor) are lectin receptors that were found to be over expressed in several
human neoplastic hepatocytes118 and

HCC cell lines including Hep G2 and

Huh7.5 cells119,120. ASGPRs selectively binds and internalize different molecules
exposing

carbohydrate

residues

as

galactose,

galactosamine,

or

N-

acetylgalactosamine through clathrin type receptor mediated endocytosis121,122.
Galactosamine was proven to achieve ASGPR mediated efficient liver
tumor targeting in phase I clinical trial of poly[N-(2-hydroxypropyl)methacrylamide]
copolymer carrying doxorubicin and galactosamine, as reported by Peter J. Julyan
and co workers123. In the same line, Zheyu Shen, et al. showed increased cellular
uptake and cytotoxicity of galactosamine targeted doxorubicin loaded albumin
nanoparticles compared to non-targeted counterparts124. Similarly, Yu Cai Wang
et al. demonstrated that galactosamine conjugated micelles loaded with paclitaxel
exhibited better drug internalization, cytotoxicity and induction of cell cycle arrest
in contrast to the paclitaxel loaded micelles without galactosamine ligand 125. As a
result, galactosamine is a well-studied effective targeting moiety for hepatoma cells
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expressing ASGPR. Galactosamine conjugated delivery systems could thus be
very promising in achieving more effective HCC therapy, with better accumulation
of therapeutic agents in the tumor tissue and lesser side effects.
In the present work, we engineered polymeric nanomicelles which can be
multifunctional in use and can be utilized as modular platform for delivering
chemotherapeutic drugs, imaging agents, and genes/siRNA simultaneously or
individually, in a targeted manner to one or more cancer type. Our amphiphilic
micellar copolymer is composed of SMAPIE copolymer grafted to hyperbranched
PEI polymer, with the hydrophobic styrene groups forming the compact micellar
core and the hydrophilic polyethylenimine amino branches forming the coronal
layer. The role of PEI is for efficient complexation of siRNAs and genes. We
partially converted primary amine groups in PEI polymer to azide groups, so that
copper free “click” chemistry could be employed to conjugate targeting ligands or
imaging moieties to decorate the nanomicelles. As a proof-of-concept in this study
we synthesized galactosamine targeted nanomicelles for selective delivery of Nrf2
siRNA in HCC cells. As illustrated in figure 1.4, the targeted micelles were able to
achieve selective high cellular uptake via ASGPR mediated endocytosis and
statistically significant Nrf2 gene knockdown in the tested HCC.
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Figure 1.4. Schematic illustration of galactosamine conjugation to the modular
polymeric SMAPIE-PEI-N3 micelles, the SMAPIE-PEI-Gal micelleplexes formation
followed by their uptake in HCC cells via receptor mediated endocytosis to achieve
siRNA mediated Nrf2 gene knockdown.
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CHAPTER 2 EXPERIMENTAL DESIGN
2.1 Materials
Branched polyethylenimine (PEI) with average molecular weight 10 KDa
was purchased from polysciences (Warrington, PA). Branched polyethylenimine
(PEI) with average molecular weight 25 KDa, Poly(styrene-co-maleic anhydride,
partial iso-octyl ester) cumene terminated (SMAPIE) with average molecular
weight 2.3 KDa, β-D(+)-Glucose, Glycine, Ammonium persulfate, Glycerol,
Sodium

dodecyl

sulfate,

2-

Mercaptoethanol,

N,N,N′,N′-

Tetramethylethylenediamine, MISSION siRNA Universal Negative Control #2
(SIC002), and RNAase free water, were purchased from Sigma-Aldrich (St Louis,
MO, USA). D-(+)-Galactosamine.HCl was obtained from MP BioMedicals, LLC
(Solon, OH, USA). Dibenzyl cyclooctyne – (polyethylene glycol)

5

–N-hydroxy

succinimide (DBCO-PEG5-NHS) ester was purchased from Click Chemistry Tools
Bioconjugate Technology Company (Scottsdale, AZ, USA). Potassium carbonate
was purchased from Fisher science education (Nazareth, PA, USA). Pyrene was
from Acros (NJ, USA). SYBER Gold nucleic acid gel stain was obtained from
Invitrogen life technologies (Carlsbad, CA, USA).
medium (DMEM), FluoroBrite
Phosphate-buffered saline

TM

Dulbecco’s modified eagle

DMEM life cell fluorescence imaging medium,

(PBS), fetal

bovine

serum

(FBS),

penicillin-

streptomycin (Pen-Strep), and Trypsin-EDTA (0.25%) with phenol red solution
were from Gibco, Thermo Fisher Scientific (Waltham, MA, USA). Tris base
(hydroxyl Methyl amino Methane), Pierce protease and phosphatase inhibitor mini
tablets, and Super Signal West Pico chemiluminescent substrate were obtained
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from Thermo Fisher Scientific (Waltham, MA, USA). Goat anti-mouse IgG-HRP sc2005 secondary antibody, Nrf2 (A-10) sc-365949 mouse monoclonal primary
antibody, GAPDH (G-9) sc-365062 mouse monoclonal primary antibody, and Nrf2
siRNA (h) sc-37030 were purchased from Santa Cruz Biotechnology, Inc. (Dallas,
TX, USA). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
was obtained from Gold Biotechnology (St Louis, MO, USA). Silencer® FAM™Labeled Negative Control #1 siRNA was obtained from Applied Biosystems
Ambion, Inc. (Austin, TX, USA). Lyso Tracker Deep Red fluorescent dye, and
Hoechst 33342, Trihydrochloride Trihydrate nucleic acid stain were purchased
from Life Technologies (Carlsbad, CA, USA). Bradford protein assay dye reagent
concentrate, 10% Tween 20 solution, and 30% Acrylamide/Bis solution were
bought

from

BIO-RAD

(Hercules,

CA,

USA).

Imidazole-1-sulfonylazide

hydrochloride reagent was synthesized in our lab according to previously reported
method126. All other reagents and Solvents were of analytical grade and were used
without further purification.
2.2 Cell Culture
The human HCC cell line (Hep G2) was a kind gift from Dr. John J. Reiners
(Wayne State University, Detroit, MI, USA). Cells were cultured in DMEM medium
supplemented with 10% fetal bovine serum (FBS), 4 mM L-Glutamine, (4.5 g/L Dglucose), (3.7 g/L sodium bicarbonate) and 1% penicillin-streptomycin solution at
37 C
̊ in humidified air containing 5% CO2. Cells were maintained and sub-cultured
every 3 to 4 days at approximately 80% confluency.
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2.3 Synthesis and Characterization of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal
Micelles
2.3.1 Synthesis of SMAPIE-PEI-N3 Micelles Forming Block Copolymer

SMAPIE-PEI-N3 micelles were synthesized in two steps by one pot reaction
method. First, previously reported method 127 was followed, with some
modifications. Briefly, PEI 10 KDa (250 mg, 0.025 mmole) was dissolved in 47 mL
methanol followed by addition of 23 mL DMSO to it. SMAPIE 2.3 KDa (57.5 mg,
0.025 mmole) was dissolved in 23 mL DMSO followed by addition of 47 mL
methanol. Subsequently, SMAPIE solution was added in a dropwise fashion onto
the PEI 10 KDa solution with continuous stirring using a magnetic stirrer. The
dropping rate was fixed at about 12 drops/min. The reaction mixture was then kept
under continuous stirring at room temperature overnight.
In the next step, conversion of some of the primary amine groups in PEI to
azide groups was undertaken using a previously published method126, with some
modifications. In brief, potassium carbonate (216.4 mg, 1.566 mmole) was added
to the crude reaction mixture from the previous step while stirring on ice, followed
by the portion wise addition of imidazole-1-sulfonylazide hydrochloride reagent
(109.4 mg, 0.522 mmole). The ice bath was removed and the reaction was kept
under stirring at room temperature for 24 hours. The reaction mixture was then
dialyzed using dialysis bag (MWCO 10KDa, Spectra/Por, Spectrum Labs, San
Diego, CA, USA) against deionized water for 2 days with frequent changes of the
dialysis water to remove solvents, salts and any small molecular weight unreacted
reagents. Then, the dialysis was continued against deionized water for another 6
hours using a dialysis bag (MWCO 12-14 KDa, Spectra/Por, Spectrum Labs, San
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Diego, CA, USA) to get rid of unreacted PEI. The final dialyzed product was filtered
using Whatman filter paper to remove any precipitate or crosslinked product. The
dry SMAPIE-PEI-N3 product was obtained by lyophilization (yield 86%).
The successful synthesis of SMAPIE-PEI-N3 product was confirmed by
Fourier transform infrared spectroscopy (JASCO, FT/IR - 4200 Fourier Transform
Infrared Spectrometer, Japan) and Proton nuclear magnetic resonance (1H NMR)
spectroscopy (600 MHz, Agilent-NMR-inova600, Santa Clara, CA, USA).
FT-IR (ν, cm-1): 2500-3700 (carboxylic acid broad –OH stretch), 2105 (azide
–N3 stretch), 1749 (ester –C=O stretch), 1700 (little shoulder of carboxylic acid –
C=O stretch), 1671 (secondary amide –C=O stretch), 1519 (aromatic benzene ring
C=C stretch).
1H

NMR (d4-CD3OD): δ (ppm) = 0.86 (overlapping peaks of: -CH3 in cumene

terminal and –CH(CH3)2 in iso-octyl chain), 1.15-1.8 (overlapping peaks of: –
CH(CH3)2, -CH2 - in iso-octyl chain and -CH2CHPh), 2.2-3 (-CH2CH2NH- in PEI),
3.1-3.6 (overlapping peaks of: -COCH-, -OCH2-, -CH2NHCO- and -NHCH2CH2N3
in PEI chain), 6.4-7.4 (C6H5- in cumene terminal and styrene residues).
2.3.2 Synthesis of Targeting Ligand Conjugated SMAPIE-PEI-Gal Micelles
Forming Block Copolymer

Galactosamine targeted micelles, SMAPIE-PEI-Gal, were synthesized by

copper free “click” chemistry according to a protocol provided by Click Chemistry
Tools company (Scottsdale, AZ, USA) in two steps, with some modifications. First,
the galactosamine.HCl (20.2 mg, 0.0936 mmole) was dissolved in 3mL 1X
phosphate buffer saline (PBS). Then, triethylamine (Et 3N) (13 µl, 0.0936 mmole)
was added to the solution to obtain the galactosamine in its basic form so that it
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can efficiently react with the NHS ester. DBCO-PEG 5-NHS ester (21.65 mg,
0.0312 mmole) was dissolved in 400 µl DMSO and then added to the solution
containing galactosamine to obtain the product, galactosamino-PEG 5-DBCO. The
reaction mixture was kept under stirring at room temperature for 6 hours in order
to allow the reaction to proceed to completion.
In the next step, galactosamino-PEG5-DBCO obtained in the first step was
reacted with SMAPIE-PEI-N3 micelles as follows: SMAPIE-PEI-N3 (50 mg) was
dissolved in 7 mL deionized water and added to the solution containing
galactosamino-PEG5-DBCO obtained from step one. The reaction mixture was
stirred at room temperature for 12 hours. The product was dialyzed using a dialysis
bag (MWCO 10KDa, Spectra/Por, Spectrum Labs, San Diego, CA, USA) against
deionized water for 1 day with frequent changes to the dialysis water to remove
solvents, salts and any small molecular weight unreacted reagents. The dried final
product, SMAPIE-PEI-Gal was obtained by lyophilization (yield 99%).
The successful synthesis of SMAPIE-PEI-Gal targeted micelles forming
block copolymer was confirmed by proton nuclear magnetic resonance ( 1H NMR)
spectra recorded on 600 MHz spectrometer (Agilent-NMR-inova600, Santa Clara,
CA, USA).
1H

NMR (d2-D2O): δ (ppm) = 1.4 (overlapping peaks of: -CH3 in cumene

terminal and -CH(CH3)2 in iso-octyl chain), 1.7 (overlapping peaks of: -CH2 - in isooctyl chain and -CH2CHPh), 2.2-3 (-CH2CH2NH- in PEI), 3-3.49 (overlapping peaks
of: -COCH-, -OCH2- in SMAPIE, -CHNH2 protons in galactosamine alpha and beta
anomers and -OCH2CH2O- in PEG chain), 3.5-4 (-CH2CHCHOH, -NH2CHCHOH,
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-CH2OH, -CHCH2- protons in galactosamine alpha and beta anomers), 4.5, 5 (OCHOH alpha and beta anomeric protons in galactosamine), 6.4-7.6 (overlapping
peaks of: -C6H4 in substituted DBCO and -C6H5 in cumene terminal and styrene
residues).
2.4 Size Exclusion Chromatography (SEC)
Gel

filtration

chromatography

(GFC),

a

type

of

size

exclusion

chromatography, was performed to determine the molecular weight of SMAPIEPEI-N3 micelles relative to molecular weight of protein standards. Briefly, the
samples were prepared in 0.45 µm filtered deionized water (6 mg/mL) and
sonicated using Branson 8210 ultrasonifier for 20 min. The sample was then
injected in Hiload 16/600 Superdex 75 pg column in AKTA FPLC system (GE
Healthcare Lifesciences, Pittsburgh, PA, USA). The sample was run at a flow rate
0.3 mL/min using (300 mM NaCl, 50 mM Na2HPO4/NaH2PO4, 10% acetonitrile) as
running buffer (pH 7.2) at 4˚C. UV detector was set at 280 nm for detection of
aromatic benzene ring in SMAPIE chain. Elution volume was used to calculate the
relative molecular weight using standard curve of log molecular weights of protein
standards versus standards Ve/Vo (elution volume/ column void volume).
2.5 Copper Assay
A copper based assay was performed to quantify the amount of PEI in
SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles according to previously described
method128. Briefly, using a 96 well plate, 50 µL of 20 mM copper acetate in 5% Na
acetate solution was added to 50 µL of either SMAPIE-PEI-N3 or SMAPIE-PEIGal solution (2 mg/mL) in deionized water. The intensity of the blue colored
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cuprammonium complex was measured at 690nm on a synergy 2 microplate
reader (BioTek Instrument, Winooski, VT, USA).
The concentration of PEI in targeted and non-targeted micelles was
calculated based on the calibration curve constructed using PEI 10 KDa as
standard at varied concentrations (2, 1, 0.5, 0.25, 0.125, 0.0625 mg/ml). Results
were presented as mean (± SD), n=3 and n=4 in case of PEI 10 KDa standard and
micelles respectively.
2.6 Determination of Critical Micelle Concentration (CMC)
CMC was determined by fluorescence spectroscopy using pyrene as a
fluorescent probe4. Briefly, 100 µl of pyrene solution in methanol (12 µM) was
added into amber colored bottles and left in chemical hood overnight to allow
methanol evaporation and pyrene film formation. Then varying copolymer
concentrations in water (0.0001-0.5 gm/L) was prepared in triplicates and added
to the pyrene film to get pyrene final concentration of (0.6 µM). The solutions were
kept on a shaker at room temperature for 24 hours. Subsequently, the
fluorescence

measurement

was

performed

on

F-2500

fluorescence

spectrophotometer (Hitachi,Ltd. Tokyo, Japan). The measurements were done at
excitation wavelengths of 334 nm and 339 nm and emission wavelength of 390
nm. The emission intensity ratio (I339/I334) was plotted against the logarithm of
the copolymer concentrations. The CMC value was obtained from the intersection
of the tangential lines on the curve as reported previously130. Results were reported
as mean (± SD, n=3).

26

2.7 Preparation of siRNA Micelleplexes or Polyplexes
Micelleplexes or polyplexes were prepared according to the pre-calculated
N/P ratio, which is the ratio of positively charged amine groups (N) in the polymer
to the negatively charged phosphate groups (P) in siRNA. Both micelles/polymer
and siRNA solutions were prepared in sterile filtered 5% glucose solution using
0.22 µm syringe filter. Equal volumes of siRNA solution and micelles/polymer
solution were efficiently mixed and pipetted many times, then incubated at room
temperature for 30 min to allow efficient complexation. Micelles/polymer solutions
of different concentrations were used to form micelleplexes or polyplexes at the
desired various N/P ratios.
2.8 SYBER Gold Assay
SYBER Gold quenching assay was performed to evaluate the siRNA
condensation capacity of both targeted (SMAPIE-PEI-Gal) and non-targeted
(SMAPIE-PEI-N3) micelles at different N/P ratios (1, 2, 3, 4, 5, 10, 15) in
comparison to PEI 25 KDa and PEI 10 KDa as controls. SYBER Gold assay was
conducted according to previously reported procedure131 with some modifications.
For this purpose, white/opaque FluoroNunc 96 well plate was used. In each well,
50 pmol of siRNA Universal Negative Control #2 in 50 µL of sterile 5% glucose
solution was complexed with 50 µL of micelles or polymer solution prepared at the
suitable concentration in sterile 5% glucose solution to achieve the desired N/P
ratio. The (100 µL) in each well was incubated for 30 minutes at room temperature.
Then, 30 µL of 4x SYBER Gold solution was added to each well and the plate was
incubated in the dark at room temperature. After 15 minute incubation,
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fluorescence was detected using a synergy 2 microplate reader (BioTek
Instrument, Winooski, VT, USA) at excitation and emission wavelength of
485/20nm and 528/20nm respectively. Results were represented as mean (±
standard deviation, n=3). Fluorescence intensity at N/P = zero (free siRNA +
SYBER Gold dye) was set as 100% and relative fluorescence intensities of
micelleplexes or polyplexes was obtained using the equation: [(micelleplexes or
polyplexes fluorescence intensity) / (fluorescence intensity at N/P= zero)]* 100.
2.9 Size and Zeta Potential Measurements: Light Scattering (LS)
Hydrodynamic size and zeta potential measurements of siRNA free
micelles, siRNA containing micelles (micelleplexes) and PEI 10 KDa polyplexes
were performed in triplicates using light scattering (LS) analysis. All samples were
tested in a Zetasizer Nano ZS (Malvern Instruments, Westborough, MA, USA) at
25 ̊C. The siRNA free micelles samples were prepared in deionized water (1mg/ml)
and tested at a volume of 350 µl and 750 µl using disposable cuvettes for size and
zeta potential determination respectively. Micelleplexes or PEI polyplexes sizes
were measured by transferring 100 µl of micelleplexes or PEI polyplexes solution
in sterile filtered 5% glucose to low volume disposable cuvette, where each 100 µl
contained 20 pmol of siRNA. After size measurement, the same sample (in 100 µl
volume) was diluted with 650 µl sterile filtered 5% glucose solution and transferred
into transparent zeta cuvette for zeta potential measurements using the same
instrument. The scattered light was detected at 173˚ backscatter angle, distilled
water viscosity and refractive index of (0.8872 cP) and (1.33) respectively, were
used as measuring parameters. Samples in triplicates where tested and three

28

measurements were performed for each sample with at least 12 runs per
measurement. Size and zeta measurements Results were presented as Z-average
hydrodynamic size in nanometers (± SD, n=3) and mean in millivolts (± SD, n=3),
respectively.
2.10 Size and Morphology
Microscopy (TEM)

Measurements:

Transmission

Electron

The size and morphology of siRNA free micelles and micelleplexes in the

dry state were obtained by transmission electron microscopy TEM. TEM samples
were prepared by adding a drop of siRNA free micelles solution (4mg/ml), or
micelleplexes solution (prepared as described above at N/P ratio of 10 with 40
pmol siRNA Universal Negative Control #2 in total volume of 10 µl) on a coppercoated grid (200 mesh) for 3 minutes followed by blotting the grid, and staining
with 3% uranyl acetate for another 3 minutes. Finally, the grid was allowed to air
dry completely before imaging. Sterile filtered 5% glucose solution was used as
the dispersion medium for sample preparation. Several images at different
magnifications were obtained for each sample with a transmission electron
microscope (JEOL 2010 TEM, LaB6 Filament Gun, Tokyo, Japan).
2.11 Buffering Capacity Measurements
An acid-base titration was performed to determine the buffering capacity of
both targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEI-N3 micelles in
comparison to PEI branched polymers of different molecular weights (25, 10, 1.8
KDa) as positive controls and 150 mM NaCl solution as vehicle and negative
control. The assay was done according to previously reported procedure 132.
Briefly, 3 mg polymer or micelles were dissolved in 15 ml of 150 mM NaCl solution
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to achieve final concentration of 0.2 mg/mL. The pH of all solutions was adjusted
at the beginning to 11.0 by titration against 0.1 M NaOH solution. Subsequently,
titration curve was generated for each polymer or micelle by titrating their solutions
with 0.1 M HCl solution at equal increments of 30 µL till pH of 2.0. The changes in
pH values were determined after each 30 µL addition using a pH meter at room
temperature. The slower the change in the pH of the solution during titration the
higher its buffering capacity and vice-versa.
2.12 Biological Evaluation of SMAPIE-PEI-N3 and SMAPEI-PEI-Gal Micelles
2.12.1 Cytotoxicity Assay Using Human Liver Cancer Cells
The cytotoxicity of free polymers (PEI 25 KDa and PEI 10 KDa as controls)
or micelles (non-targeted SMAPIE-PEI-N3 and targeted SMAPIE-PEI-Gal) was
studied using MTT assay on Hep G2 human HCC cells. The Hep G2 cells were
seeded in 96 well plates at cell density of 5000 cells/well in 100 µL of DMEM growth
medium containing 10% FBS and incubated for 24 hours at 37 ̊C in humidified air
containing 5% CO2. Stock solutions of different polymers or micelles were
prepared in sterile 5% glucose solution. Predetermined concentrations were
obtained by serial dilution of the respective stock solutions with cell culture medium
supplemented with FBS. Subsequently, 100 µL of each serial dilution was added
on the preexisting 100 µL media in each well to achieve final polymer or micellar
concentrations ranging from 400 to 1.5625 µg/mL. The cells were incubated for 48
hours. MTT solution in phosphate buffered saline (PBS; 5 mg/mL) was then added
to cells (20 µL/well), and the plates were incubated for additional 3 hours at 37 ̊ C
and 5% CO2. Then, all the media were removed and 100 µL of dimethyl sulfoxide

30

(DMSO) was added in each well and the plates were subjected to orbital shaking
in the dark for 15 minutes. The DMSO solvent dissolved the purple colored
formazan crystals formed in the mitochondria of live cells. The absorbance was
recorded at 590 nm on a synergy 2 microplate reader (BioTek Instrument,
Winooski, VT, USA). Results were presented as mean (± SD, n=3) of relative cell
viability (%). Percentage relative cell viability = (treated cells absorbance – blank

absorbance) / (untreated cells absorbance – blank absorbance) х 100. Treated and
untreated cells are cells cultured in presence or absence of polymers or micelles,
respectively. Blank values (controls) were attributed to the absorbance measured
in wells that didn’t contain cells.
2.12.2 Cellular Uptake Quantification by Flow Cytometry
Flow cytometry was used to quantify the cellular uptake of the fluorescently
labeled micelleplexes or polyplexes. Hep G2 cells were seeded in 24 well plates
at cell density of 80,000 cells/well in 500 µL of DMEM containing 10% FBS and
incubated for 24 hours at 37 ̊C and 5% CO2 prior to transfection. On transfection
day, pre-existing medium was replaced with 350 µL fresh media containing 10%
FBS. In case of competition assay, the 350 µL of fresh DMEM medium contained
10% FBS and 20 mM free galactosamine as a competitor of galactsamine in
SMAPIE-PEI-Gal micelles. PEI 10 KDa polyplexes, targeted (SMAPIE-PEI-Gal)
or non-targeted (SMAPIE-PEI-N3) micelleplexes were prepared as described
above in 50 µL of sterile 5% glucose solution at N/P ratio of 10 using fluorescent
FAM™-Labeled

Negative

Control

siRNA.

The

prepared

polyplexes

or

micelleplexes were added on cells to achieve final siRNA concentration of 200 nM
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per well. Untreated cells (blank) or cells treated with free siRNA served as negative
controls, while cells treated with PEI 10 KDa polyplexes served as positive control.
After the polypexes or micelleplexes addition, cells were incubated at 37 ̊ C and 5%
CO2 for total transfection time of 5 hours. When the transfection period ended, the
transfection medium was removed, and cells were washed with 1 mL sterile PBS.
100 µL trypsin /well was added for 3 minutes to detach cells followed by addition
of 900 µL fresh medium to deactivate the trypsin. Cell suspensions were collected
and centrifuged at 4 ̊C for 5 minutes at 800 rpm, then supernatant was removed
and cells were washed with 1mL sterile PBS by resuspension and recentrifugation. Finally, cells were re-suspended in 400 µL sterile PBS for
fluorescence quantification using Attune® Acoustic Focusing Flow Cytometer
(Applied Biosystems, Life Technologies, Carlsbad, CA,USA). The laser beam was
set at a wavelength of 488 nm for excitation and (530/30) (center/band pass)
emission filter was used for emission detection. Cells were gated based on their
morphology and 10,000 events were evaluated per each sample. Measurements
were performed in triplicates and data analysis was performed using Attune®
Cytometric Software. Data are shown as mean of median fluorescence intensity (±
standard deviation, n=3). Statistical analysis of data was completed through oneway ANOVA and post hoc Tukey HSD test application using Vassar stats program.
2.12.3 Cellular Uptake and Endosomal Escape by Confocal Laser Scanning
Microscopy (CLSM)

Cellular uptake of both targeted (SMAPIE-PEI-Gal) and non-targeted

(SMAPIE-PEI-N3) micelleplexes through endocytosis and the ability to achieve
endosomal escape with the release of the siRNA in cytoplasm was shown by

32

Confocal Laser Scanning Microscopy (CLSM, Leica microsystems, Mannheim,
Germany). Hep G2 cells were seeded in 4 well µ-Slide Ph+, ibiTreat ( ibidi,
Wisconsin, USA) at cell density of 35,000 cells/well in 600 µL of FluoroBrite

TM

DMEM life cell fluorescence imaging medium containing 10% FBS and incubated
for 24 hours at 37 ̊C in humidified air containing 5% CO2 prior to transfection. On
day of transfection pre-existing medium was replaced with 550 µL of fresh
FluoroBrite TM DMEM medium containing 10% FBS. In case of competition assay,
the 550 µL of fresh FluoroBrite

TM

DMEM medium contained 10% FBS and free

galactosamine as a competitor of galactsamine in SMAPIE-PEI-Gal micelles. The
free galactosamine was added to obtain final concentration of 100 µg/ml in total
volume of 600 µL. Cells were transfected with micelleplexes or polyplexes at N/P
ratio of 10. Polyplexes of PEI 10KDa as a positive control or micelleplexes of
targeted (SMAPIE-PEI-Gal) or non-targeted (SMAPIE-PEI-N3) micelles were
formed as described above using Silencer® FAM™-Labeled Negative Control
siRNA in 50 µL of sterile 5% glucose solution, which was then added to the 550
µL of fresh medium in each well to achieve final siRNA concentration of 200 nM.
Then, cells were incubated for 20 hours at 37 ̊C and 5% CO2 before being washed
with PBS PH 7.4. Subsequently, cells were incubated for 1 hour in 100 nM Lyso
Tracker Deep Red dye solution in FluoroBrite

TM

DMEM medium containing 10%

FBS to stain endosomes. Then, cells were washed with PBS PH 7.4. The nuclei
were stained with 8.115 µM Hoechst 33342 stain solution in PBS following
incubation of cells with the stain at 37 ̊C and 5% CO2 for 10 minutes. Finally, cells
were washed with PBS and incubated in 700 µL FluoroBrite

TM

DMEM medium
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containing 10% FBS. The cells were directly imaged by live cell imaging technique
on Leica TCS SP5 inverted confocal microscope (Leica microsystems, Mannheim,
Germany). All images were acquired using oil immersion lens with 63X
magnification / 1.4 numerical aperture. For excitation of Hoechst 33342, FAMLabeled siRNA, and LysoTracker Deep Red Laser beams with excitation
wavelengths 405nm, 488nm, and 633nm were used respectively. Merge images
of the three fluorescent emissions as well as Bright field ones were recorded for
each sample.
Fiji ImageJ software (Life-Line version, 2015 December 22) 133,134 was used
for quantification of green siRNA fluorescence in the CLSM images. Fluorescence
quantification was performed according to previously reported method135. Total
corrected cellular fluorescence (TCCF) per cell was determined, where TCCF =

integrated density obtained – (area of selected cell х fluorescence of background).
After that, mean of TCCFs of all cells / image was calculated and plotted against
each treatment type.
2.12.4 Transfection Efficiency and Nrf2 Gene Knockdown by Western Blot
Analysis
SMAPIE-PEI-Gal micelleplexes transfection efficiency and Nrf2 gene

knockdown in Hep G2 cells were evaluated using western blotting technique. Nrf2
gene knockdown mediated by Nrf2 siRNA condensing SMAPIE-PEI-Gal
micelleplexes was compared to that mediated by the positive transfection control
Nrf2 siRNA condensing PEI 10 KDa polyplexes. As negative controls, siRNA
Universal Negative Control #2 condensing micelleplexes and polyplexes were also
prepared and tested. Briefly, all micelleplexes and polyplexes were prepared at
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N/P ratio of 10 as described above in total volume of 100 µL of sterile 5% glucose
solution containing 55 pmol siRNA. In 6 well plates, reverse transfection technique
was applied for transfecting Hep G2 cells. In each well, 100 µL of the micelleplexes
or the polyplexes were added, followed by the addition of 1 ml Hep G2 cells
suspension in complete DMEM media supplemented with 10% FBS and 1%
penicillin/streptomycin at cell density 500,000 cells/ml. The final siRNA
concentration in each well was 50 nM. Plates were incubated under humidified
conditions at 37 ̊C and 5% CO2 for 5 hours. After 5 hours of incubation, 1.1 ml fresh
complete DMEM media was added in each well to obtain final volume of 2.2 ml
and cells were incubated for additional 19 hours. Subsequently, cells were
collected on ice in 15 ml centrifuge tubes, centrifuged at 4 ̊C, washed with ice cold
1x PBS solution, and then centrifuged at 4 ̊C to get the cell pellet. Whole cell lysis
buffer was then added to the cell pellets, and cells were lysed by pipetting up and
down many times. Cells were incubated with the lysis buffer on an orbital rocker at
4 ̊C for 30 minutes, then centrifuged at 120,000 rpm for 15 minutes at 4 ̊C. The
pellet was discarded and the cell lysates were collected followed by quantification
of the total protein concentration in each lysate by Bradford assay using BSA as
standard.
Samples were then prepared for loading in the 10% SDS-polyacrylamide
gel, where lysates equivalent to 40 µg total protein were denatured by mixing with
equal volume of 2x SDS-PAGE loading buffer containing β-mercaptoethanol
followed by heating at 95 ̊C for 5 minutes. Denatured samples were then loaded
on 10% SDS-polyacrylamide gel (SDS-PAGE) and proteins were separated by gel
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electrophoresis at 120 volt for 2 hours. Once separated, the proteins were then
transferred to nitrocellulose membrane at 100 volt for 1 hour on ice. The membrane
was then blocked with 5% milk in TBST buffer at room temperature for 1 hour, then
washed with TBST, and incubated overnight at 4 ̊C with 1:100 diluted Nrf2 (A-10)
sc-365949 mouse monoclonal primary antibody in 5% BSA in TBST buffer. On the
next day, the membrane was washed with TBST three times for 10 minutes each,
followed by its incubation for 1 hour at room temperature with 1:2000 diluted goat
anti-mouse IgG-HRP sc-2005 secondary antibody in 5% milk in TBST buffer.
Finally, the membrane was washed in TBST three times, followed by detection of
the bound secondary antibody HRP enzyme activity using chemiluminescent light
based detection substrate (Super Signal West Pico chemiluminescent substrate)
where the chemiluminescent immune reactive bands on the membrane were
imaged using an ImageQuant LAS4000 (GE Healthcare Bio-sciences, Pittsburgh,
PA, USA). Membranes were also probed with 1:500 diluted GAPDH (G-9) sc365062 mouse monoclonal primary antibody in 5% BSA in TBST buffer in a similar
manner for detecting the GAPDH protein as a loading control.
Western blot bands intensities were then quantified using Fiji ImageJ
software (Life-Line version, 2015 December 22)133,134. According to previously
published method, expression of Nrf2 protein reflected by the Nrf2 bands
intensities was normalized to the expression of the GAPDH loading control protein
of the same sample. Nrf2 Gene silencing efficiency was calculated by comparing
the normalized intensity of Nrf2 of sample treated with siRNA targeting Nrf2 to the
normalized intensity of Nrf2 of sample treated with negative control siRNA 136. Data
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from three independent experiments were shown as mean of normalized Nrf2
intensity or mean of [normalized Nrf2 intensity / normalized Nrf2 intensity in
negative control siRNA treated sample] (± standard deviation, n=3). Statistical
analysis of data was completed through t-tests application using Vassar stats
program.
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CHAPTER 3 RESULTS
3.1. Synthesis and Characterization of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal
Micelles
3.1.1 Synthesis of SMAPIE-PEI-N3 Micelles Forming Block Copolymer

SMAPIE-PEI-N3 was synthesized in two steps by one-pot reaction (scheme
3.1). In the first step, opening of the anhydride ring in SMAPIE copolymer (1) by
primary amine group in the branched polymer polyethylenimine (PEI) (2) to form
amide bond linking the two polymeric chains forming the di-block copolymer
SMAPIE-PEI was undertaken. In the next step, conversion of some of primary
amine

groups in PEI

to azide

groups using Imidazole-1-sulfonylazide

hydrochloride reagent as a “diazo donor”, and SMAPIE-PEI-N3 micelles forming
block copolymer (3) was obtained as the final product. The diazo-transfer reaction
was completed without any copper metal catalysis. Azide decorated micelles were
subsequently reacted with alkyne group in strained cyclooctyne ring through
copper free “click” chemistry. The final product purification was done through
membrane dialysis.
3.1.2 Synthesis of Targeting Ligand Conjugated SMAPIE-PEI-Gal Micelles
Forming Block Copolymer
Galactosamine

targeted

SMAPIE-PEI-Gal

micelles

forming

block

copolymer was synthesized by copper free “click” chemistry in two steps (scheme
3.2). In the first step, the synthesis of the alkyne decorated galactosamine targeting
ligand through coupling of N-hydroxysuccinimide part in DBCO-PEG5-NHS ester
(4) with amine group in galactosamine.HCl (5) in its basic form was undertaken.
The coupling reaction resulted in amide bond formation and galactosamino-PEG 5-
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DBCO product (6) was obtained. In the second step, strain-promoted alkyne-azide
cycloaddition (SPAAC) reaction was undertaken between galactosamino-PEG 5DBCO product (6) from the first step and SMAPIE-PEI-N3 micelles forming block
copolymer (3) to arrive at SMAPIE-PEI-Gal targeted micelles forming block
copolymer (7). SPAAC is a well-established copper free “click” reaction between
strained cyclooctyne moiety in product (6) and azide moiety in SMAPIE-PEI-N3
block copolymer (3) forming a stable triazole ring linkage. The final product
purification was done through membrane dialysis.
Scheme 3.1. Synthesis of non-targeted SMAPIE-PEI-N3 micelles forming block
copolymer (3)

39

Scheme 3.2. Synthesis of ligand targeted SMAPIE-PEI-Gal micelles forming block
copolymer (7)
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3.2 Size Exclusion Chromatography (SEC)
Size exclusion chromatography was run to detect the relative molecular
weight of the SMAPIE-PEI-N3 micelles compared to molecular weights of protein
standards. The chromatogram of SMAPIE-PEI-N3 micelles is presented in figure
3.1. The chromatogram shows unimodal molecular weight distribution. The elution
volume of the micelles (78.14 mL) was used to calculate Ve/Vo (elution volume/
column void volume). The micelles relative molecular weight (13474.58 Da) was
obtained from standard curve of 158 KDa, 44 KDa, 17 KDa and 1.35 KDa protein

Milli absorption units (mAU)

standards figure 3.2.

Elution volume (mL)

Figure 3.1. Size exclusion chromatogram of SMAPIE-PEI-N3 micelles.
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Figure 3.2. Standard curve of log molecular weights of protein standards versus
standards Ve/Vo (elution volume/ column void volume), showing SMAPIE-PEIN3 relative molecular weight determination.
3.3 Copper Assay

The relative concentration of PEI in the micelles was quantified by
spectrophotometry, using a copper based assay. Copper ions successfully and
specifically chelated primary amine groups in PEI polymer chains forming a blue
colored complex called cuprammonium complex137. The intensity of the blue
complex absorbance in the visible region was found to be in the linear range with
the PEI 10 KDa various tested concentrations (2, 1, 0.5, 0.25, 0.125, 0.0625
mg/ml). As illustrated in figure 3.3, cuprammonium complex absorbance intensities
obtained at varying PEI concentrations were used to construct standard curve of
PEI 10 KDa as a standard. The absorbance intensities of SMAPIE-PEI-N3 and
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SMAPIE-PEI-Gal complexes were applied in the standard curve equation to
determine their relative PEI composition. From the results, the PEI content was
found to be 76.92 ± 3.23% (W/W) and 54.66 ± 5.9% (W/W) for SMAPIE-PEI-N3
and SMAPIE-PEI-Gal, respectively.

Figure 3.3. Standard curve of absorbance of cuprammonium complex at different
PEI 10 KDa concentrations, showing PEI composition analysis of SMAPIE-PEI-N3
and SMAPIE-PEI-Gal micelles by copper assay.
3.4 Determination of Critical Micelle Concentration (CMC)

The ability of the amphiphilic block copolymer SMAPIE-PEI-N3 to form
micelles in water was confirmed by fluorescence spectroscopy using pyrene as a
fluorescent probe. Bathochromic shift in pyrene excitation wave length from 334
nm to 339 nm with increasing SMAPIE-PEI-N3 copolymer concentration from
0.0001 to 1mg/ml was detected (figure 3.4). The CMC of SMAPIE-PEI-N3 was
found to be as low as 0.0112mg/ml which is ~ 8.6 х 10-7 M (figure 3.5).
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Figure 3.4. Fluorescence spectra of pyrene at different SMAPIE-PEI-N3
concentrations in water, showing bathochromic shift in pyrene excitation
wavelength with increasing SMAPIE-PEI-N3 concentration.

Figure 3.5. Critical micelle concentration (CMC) Plot of I339/I334 emission ratio
versus Log concentration of SMAPIE-PEI-N3 copolymer.
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3.5 SYBER Gold Assay
The siRNA condensation ability of non-targeted SMAPIE-PEI-N3, and
targeted SMAPIE-PEI-Gal micelles was determined by SBYER Gold fluorescence
quenching assay (figure 3.6). PEI 25 KDa and PEI 10 KDa polymers were also
tested as controls for comparison. Significant SBYER Gold dye fluorescence
quenching indicates efficient siRNA condensation. Complete condensation of the
siRNA was shown in targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEIN3 micelleplexes at and above N/P ratio of 4 and 7, respectively. Both PEI 25 KDa
and PEI 10 KDa polymers were able to achieve complete siRNA condensation at
N/P ratio of 4 and higher. Non-targeted SMAPIE-PEI-N3 micelles showed lesser
siRNA complexation efficiency compared to targeted SMAPIE-PEI-Gal micelles
and PEI polymers at N/P ratios lower than 10. The siRNA condensation capacity
of all micelleplexes and polyplexes increased with increasing N/P ratio.
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Figure 3.6. Condensation/Complexation behavior of polymers or micelles to
siRNA by SYBER Gold fluorescence quenching assay at increasing N/P ratios.
3.6 Size and Zeta Potential Measurements: Light Scattering (LS)

Light scattering analysis was performed for determining the hydrodynamic
size and zeta potential of plain SMAPIE-PEI-N3 (without siRNA), plain SMAPIEPEI-Gal micelles (without siRNA) and siRNA containing targeted and non-targeted
micelles (micelleplexes) as well as PEI 10 KDa polyplexes. Results were
presented as mean (± standard deviation) from three independent experiments.
Figure 3.7.A, illustrates that SMAPIE-PEI-Gal micelles exhibited larger
hydrodynamic diameter of 240 ± 4.05 nm than SMAPIE-PEI-N3 micelles whose
size was around 160 ± 1.5 nm. As shown in figure 3.7.B, both SMAPIE-PEI-N3
and SMAPIE-PEI-Gal micelles had high zeta potential of around 38 mV ± 0.76 and
40 ± 0.67 mV, respectively. As summarized in table 3.1, polydispersity index (PDI)
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as an indication of size distribution of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal
micelles was found to be 0.25 ± 0.01 and 0.42 ± 0.03, respectively. Large particle
sizes were observed at micelleplexes and polyplexes formed at lower N/P ratios,
at N/P ratio < 7 for SMAPIE-PEI-N3 micelleplexes and at N/P ratio of 3 in case of
PEI polyplexes and SMAPIE-PEI-Gal micelleplexes. Apart from that, all the
polyplexes and micelleplexes were around 200 nm (figure 3.8). Zeta potential of
all micelleplexes and polyplexes was increased with increase in N/P ratios, with
maximum zeta potential of around 23 mV at N/P ratio of 10, in case of both targeted
and non-targeted micelleplexes (figure 3.9). Table 3.2 shows that the PDI (with its
standard deviation) was increased mostly in the case of loosely formed large sized
micelleplexes/polyplexes. However, the PDI of micelleplexes at and above N/P
ratio of 7 for SMAPIE-PEI-N3 and N/P ratio of 4 for SMAPIE-PEI-Gal was ≤ 0.39,
indicating compact micelleplexes formation.
A)

B)

Figure 3.7. Hydrodynamic diameters (A) and zeta potentials (B) of plain SMAPIEPEI-N3 and SMAPIE-PEI-Gal micelles.
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Table 3.1. Polydispersity indexes of plain SMAPIE-PEI-N3 and SMAPIE-PEI-Gal
micelles. Results are presented as average from three independent samples (n=3)
± standard deviation.
Micelles polydispersity index (Mean ± Standard deviation, n =3)
SMAPIE-PEI-N3

SMAPIE-PEI-Gal

0.25 ± 0.01

0.42 ± 0.03

2600
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2000

Size Z- Average (nm)
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0

SMAPIE-PEI-N3 micelleplex SMAPIE-PEI-Gal micelleplex
N/P 3
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N/P 5

N/P 7

PEI 10 KDa Polyplex

N/P 10

Figure 3.8. Hydrodynamic diameters of SMAPIE-PEI-N3/siRNA, SMAPIE-PEIGal/siRNA micelleplexes and PEI 10 KDa/siRNA polyplexes at the specified N/P
ratios.
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Figure 3.9. Zeta potentials of SMAPIE-PEI-N3/siRNA, SMAPIE-PEI-Gal/siRNA
micelleplexes and PEI 10 KDa/siRNA polyplexes at the specified N/P ratios.

Table 3.2. Polydispersity indexes of SMAPIE-PEI-N3/siRNA, SMAPIE-PEIGal/siRNA micelleplexes and PEI 10 KDa/siRNA polyplexes at the specified N/P
ratios. Results are presented as average from three independent samples (n=3) ±
standard deviation.
Polydispersity index (Mean ± Standard deviation, n =3)
Micelleplexes

Polyplexes

N/P ratio

SMAPIE-PEI-N3

SMAPIE-PEI-Gal

PEI 10 KDa

N/P = 4

0.34 ± 0.02

0.23 ± 0.09

0.28 ± 0.14

N/P = 7

0.34 ± 0.12

0.39 ± 0.03

0.31 ± 0.09

N/P = 3
N/P = 5

N/P = 10

0.2 ± 0.08

0.22 ± 0.28
0.34 ± 0.1

0.44 ± 0.49
0.26 ± 0.03
0.25 ± 0.11

0.49 ± 0.36
0.35 ± 0.03
0.45 ± 0.26
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3.7 Size and Morphology Measurements: Transmission Electron Microscopy
(TEM)
TEM images illustrated the size and morphology of plain micelles (without

siRNA) and micelleplexes (with siRNA) in the dry state (figure 3.10). Globular
compact structure of darkly stained shell and white (unstained) core was obvious.
SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles (without siRNA) were of size ̴ 100
nm and ̴ 200 nm, respectively. At N/P ratio of 10, non-targeted micelleplexes
displayed a size of

̴ 160 nm, while galactosamine targeted micelleplexes

displayed a size of ̴ 130 nm. The TEM size, in the dry state, were relatively smaller
than the ones obtained from DLS measurements, which is the hydrodynamic size.
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A)

C)

D)

B)

E)

F)

Figure 3.10. Transmission electron microscopy images illustrating size and
morphology of SMAPIE-PEI-N3 micelles (without siRNA) (A and B), SMAPIE-PEIGal micelles (without siRNA) (C and D), SMAPIE-PEI-N3 micelleplexes (E), and
SMAPIE-PEI-Gal micelleplexes (F). Micelleplexes were prepared at N/P ratio of
10. Micelles and micelleplexes were negatively stained with 3% uranyl acetate
stain.
3.8 Buffering Capacity Measurements

The ability of polycationic vectors to escape out of endosomes and release
their cargo into the cell cytoplasm is an important property for intracellular siRNA
release and can be determined by their buffering capacity100. The buffering
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capacity is evaluated by the amount of protons required for reducing pH in the
endosomal pH range of (7-5.5)138. An acid-base titration experiment was
performed to estimate buffering abilities of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal
micelles in comparison to PEI polymers and 150 mM NaCl solution (figure 3.11).
During acid titration, small pH changes were observed in case of all PEI polymers,
as well as, SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles, while 150 mM NaCl
solution showed an opposite scenario of abrupt pH drop. All titration curves of PEI
polymers, SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles showed two inflection
points at pH ranges of (11-9) and (7-5.5). SMAPIE-PEI-N3 micelles titration data
illustrated that they had a little lower proton buffering ability than SMAPIE-PEI-Gal
micelles and PEI polymers of different molecular weights. On the other hand,
SMAPIE-PEI-Gal micelles showed comparable buffering capacity to that of PEI
polymers.
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Figure 3.11. Acid base titration profile of non-targeted SMAPIE-PEI-N3, targeted
SMAPIE-PEI-Gal micelles forming block copolymers and PEI polymers of different
molecular weights (25, 10, 1.8 KDa) at pH range (11-2).
3.9 Biological Evaluation of SMAPIE-PEI-N3 and SMAPEI-PEI-Gal Micelles
3.9.1 Cytotoxicity Assay Using Human Liver Cancer Cells
The in vitro cytotoxicity of PEI polymers, non-targeted SMAPEI-PEI-N3, and
targeted SMAPEI-PEI-Gal micelles was investigated in HepG2 cells. Results
demonstrated the following order: SMAPEI-PEI-Gal < PEI 10 KDa < SMAPEI-PEIN3 < PEI 25 KDa for their cytotoxicity and inhibitory concentration IC50 (figure 3.12).
IC50 values were found to be approximately 12, 70, 130, and 240 µg/mL for PEI 25
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KDa, SMAPEI-PEI-N3, PEI 10 KDa, and SMAPEI-PEI-Gal, respectively after 48
hours of incubation with cells. Cell viability was more than 80% in case of SMAPEIPEI-N3, SMAPEI-PEI-Gal, and PEI 10 KDa at concentration below 20 µg/mL.
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120

PEI 25KDa
PEI 10KDa

100

SMAPIE-PEI-N3

SMAPIE-PEI-Gal

80
60
40
20
0

0

50

100

150

200

250

300

Polymer concentration (µg/ml)

350

400

450

Figure 3.12. Plot showing cytotoxicity analysis of SMAPIE-PEI-N3, and SMAPIEPEI-Gal copolymers in comparison with PEI 25 KDa and PEI 10 KDa as polymeric
controls. Analysis was done on Hep G2 cells by MTT assay with concentration
range (0 – 400 µg/mL) and incubation time of 48 hours.
3.9.2 Cellular Uptake Quantification by Flow Cytometry

SMAPIE-PEI-N3 or SMAPIE-PEI-Gal micelleplexes, and PEI 10 KDa
polyplexes were prepared with fluorescent FAM-labeled siRNA at N/P ratio of 10
to evaluate and quantify their differential uptake into asialoglycoprotein receptor
(ASGPR) positive Hep G2 cells. As shown in figure 3.13.A, after 5 hours incubation
of the different samples with Hep G2 cells, the amount of siRNA-carrier complexes
internalized into cells as reflected by the detected fluorescence intensity was in the
following order : SMAPIE-PEI-Gal micelleplexes ˃ SMAPIE-PEI-N3 micelleplexes
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˃ PEI 10 KDa polyplexes ˃ free FAM-labeled siRNA ˃ untreated cells. Figure
3.13.B, demonstrates that the cellular uptake associated fluorescence intensity for
SMAPIE-PEI-Gal micelleplexes in presence of 20 mM free galactosamine as
competitor for ASGPRs was lower when compared to the intensity for SMAPIEPEI-Gal micelleplexes samples lacking free galactosamine.
Statistical analysis of cellular uptake Median fluorescent intensity
measurements for all the samples was summarized in figure 3.14. Data revealed
no significant difference in fluorescence from free FAM-labeled siRNA cellular
uptake compared to blank untreated cells. Cellular uptake of SMAPIE-PEI-N3
micelleplexes was also not significantly different from that of the positive control
PEI 10 KDa polyplexes. However, targeted SMAPIE-PEI-Gal micelleplexes
achieved significant increase in cellular uptake as compared to both non-targeted
SMAPIE-PEI-N3 micelleplexes and PEI 10 KDa polyplexes (p ˂ 0.01) with 0.84
and 1.2 fold increase, respectively. The presence of free galactosamine
competitor, significantly decreased the targeted SMAPIE-PEI-Gal micelleplexes
cellular internalization by 0.32 fold.
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A)

B)

Figure 3.13. Histogram of flow cytometry analysis showing number of
cells/channel on Y- axis versus the fluorescence intensity detected from FAMlabeled siRNA positive Hep G2 cells. A) Shows compared fluorescence intensity
achieved at cellular uptake of SMAPIE-PEI-Gal or SMAPIE-PEI-N3 micelleplexes
prepared with FAM-labeled siRNA, to that achieved in case of PEI 10 KDa
polyplexes (positive control) and free FAM-labeled siRNA as well as untreated
cells (negative controls). B) Shows different cellular uptake associated
fluorescence intensity for SMAPIE-PEI-Gal micelleplexes in presence or absence
of 20 Mm free galactosamine as competitor.
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Figure 3.14. Plot of median fluorescent intensity of FAM- labeled siRNA positive
Hep G2 cells for quantitative determination of cellular uptake of SMAPIE-PEI-N3,
SMAPIE-PEI-Gal micelleplexes or polyplexes prepared with FAM-labeled siRNA
at N/P ratio of 10. PEI 10 KDa polyplexes were used as positive control, while free
FAM-labeled siRNA and untreated cells were as negative controls. As a
competitive assay, SMAPIE-PEI-Gal micelleplexes uptake in the presence of 20
mM free galactosmine as a competitor of galactosamine in SMAPIE-PEI-Gal was
detected. Results were obtained after 5 hours incubation of samples with cells,
and are presented as (mean ± standard deviation of n=3, ** p ˂ 0.01, ns = none
statistically significant).
3.9.3 Cellular Uptake and Endosomal Escape by Confocal Laser Scanning
Microscopy (CLSM)
Confocal laser scanning microscopy was performed to see the ability of

targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEI-N3 micelleplexes to
deliver siRNA into asialoglycoprotein receptor (ASGPR) positive Hep G2 cells as
well as to determine route of their cellular uptake. PEI 10 KDa polyplexes were
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used as positive control. Competition assay was conducted to study ASGPR
targeting ability of SMAPIE-PEI-Gal micelleplexes in absence and presence of free
galactosamine. All micelleplexes or polyplexes used for Hep G2 cells transfection
were prepared with FAM-labeled siRNA at N/P ratio of 10. Live cell images were
obtained 22 hours post transfection.
As shown in figure 3.15, the Hep G2 cells nuclei were stained with Hoechst
33342 stain (blue) in first row, acidic endosomal compartments with Lyso Tracker
Deep Red dye (red) in second row, and FAM labeled siRNA (green) in third row.
Results showed more green fluorescent siRNA within Hep G2 cell when treated
with galactosamine targeted SMAPIE-PEI-Gal micelleplexes than with nontargeted SMAPIE-PEI-N3 micelleplexes or the positive control PEI 10 KDa
polyplexes. In the competition assay, less green fluorescence per cell was seen in
cells

treated

with

SMAPIE-PEI-Gal

micelleplexes

in

presence

of

free

galactosamine compared to ones lacking free galactosamine. Although, most of
the green fluorescence from the siRNA was found in the cells cytoplasm around
the blue nucleus, however little amount was still co-localized with the acidic
endosomes as demonstrated by yellow colored spots in merged images in fourth
row. As illustrated in figure 3.16, mean of total corrected cellular fluorescence
(TCCF) was calculated to quantify the green fluorescent siRNA internalized in cells
with each treatment. TCCF was estimated for each cell, then the mean of all
TCCFs for all cells / image was obtained. The results were found to be consistent
with the ones obtained by flow cytometry quantification as mentioned above.
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Figure 3.15. Confocal laser scanning microscopy images of Hep G2 cells treated
with SMAPIE-PEI-Gal micelleplexes (column A), SMAPIE-PEI-Gal micelleplexes
plus free galactosamine competitor (column B), SMAPIE-PEI-N3 micelleplexes
(column C) and PEI 10 KDa polyplexes (column D), 22 hours after transfection.
Micelleplexes or polyplexes were prepared with FAM-labeled siRNA at N/P ratio
of 10. The cells nuclei were stained with Hoechst 33342 stain (blue), acidic
endosomal compartments with Lyso Tracker Deep Red dye (red), and siRNA was
labeled with FAM (green).
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Figure 3.16. Plot illustrating CLSM images green fluorescence quantification.
Mean total corrected cellular fluorescence (MTCCF) of internalized green
fluorescent FAM -labeled siRNA complexed with micelleplexes or polyplexes in
Hep G2 cells was calculated per image and plotted on Y axis against treatment
type on X axis.
3.9.4 Transfection Efficiency and Nrf2 Gene Knockdown by Western Blot
Analysis
SMAPIE-PEI-Gal micelleplexes or PEI 10 KDa polyplexes condensing 55
pmol Universal Negative Control siRNA (as negative control) or Nrf2 siRNA at N/P
ratio of 10, were prepared and used for transfecting Hep G2 cells by reverse
transfection technique. After 24 hours of transfection, Western blot protein
expression analysis was performed to determine and quantify Nrf2 gene
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knockdown mediated by SMAPIE-PEI-Gal micelleplexes compared to the positive
transfection control PEI 10 KDa polyplexes.
As illustrated in figure 3.17, both Nrf2 complexing SMAPIE-PEI-Gal
micelleplexes and PEI 10 KDa polyplexes mediated statistically significant Nrf2
gene knockdown (p ˂ 0.05). Nrf2 protein expression in cells treated with Nrf2
condensing SMAPIE-PEI-Gal micelleplexes was 0.49 fold lower than cells treated
with negative control siRNA condensing SMAPIE-PEI-Gal micelleplexes. Similarly,
Nrf2 protein expression in cells treated with Nrf2 condensing PEI 10 KDa
polyplexes was 0.27 fold lower than cells treated with negative control siRNA
condensing PEI 10 KDa polyplexes. However, the Nrf2 gene knockdown mediated
by SMAPIE-PEI-Gal micelleplexes was 21% higher than that mediated by PEI 10
KDa polyplexes (p ˂ 0.05).
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Figure 3.17. Western blot bands of Nrf2 and GAPDH protein levels detected in
Hep G2 cells after 24 hours transfection with SMAPIE-PEI-Gal micelleplexes or
PEI 10 KDa polyplexes condensing 50 nM Nrf2-siRNA or negative control siRNA
(NCr-siRNA) at N/P ratio of 10 (A). Estimation of Nrf2 gene silencing efficiency
accomplished by SMAPIE-PEI-Gal micelleplexes versus PEI 10 KDa polyplexes
through quantification of the above western bands intensities, data presented as
mean of (GAPDH normalized Nrf2 protein level/GAPDH normalized Nrf2 protein
level in case of NCr-siRNA plexes treatment) ± standard deviation, n=3, and * p ˂
0.05 statistical significance (B).
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CHAPTER 4 DISCUSSION
4.1 Synthesis and Characterization of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal
Micelles
4.1.1 Synthesis of SMAPIE-PEI-N3 Micelles Forming Block Co-polymer

SMAPIE-PEI-N3 micelles forming block co-polymer was synthesized from
SMAPIE 2.3 KDa copolymer and branched PEI 10 KDa polymer. PEI polymer of
moderate molecular weight and optimal number of cationic groups was chosen for
the synthesis since it has better nucleic acids condensation and transfection
efficiency than the lower molecular weight ones and at the same time it induces
lesser cytotoxicity compared to higher molecular weight PEI chains139. SMAPIE
copolymer has hydrophobic styrene groups and iso-octyl chains that can help in
self-assembly and formation of the micelles by hydrophobic interactions.
SMAPIE-PEI-N3 micelles forming block co-polymer was synthesized in two
steps by one-pot reaction. The one-pot reaction module afforded several
advantages including faster and easier product synthesis, lesser purification steps
(no necessary purification of the intermediate and only purification was done for
the final product), and hence enabled better product yield. In the first step, SMAPIE
and PEI were reacted in equimolar ratio to give a water soluble diblock-copolymer.
It was noted that increasing the molar ratio of SMAPIE compromised the water
solubility of the so-formed diblock-copolymer. In the second step, partial
conversion of primary amine groups in PEI to azide groups was achieved in order
to create azide moieties for targeting ligands attachment through strain promoted
alkyne azide cycloaddition (SPAAC) “click” reaction (figure 4.1), while at the same
time preserving good share of the cationic amine groups for siRNA or gene
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condensation and delivery. It is important to note that we succeeded to complete
the diazo-transfer reaction without copper metal catalysis compared to what was
previously published126. In addition, targeting ligand attachment to the block copolymer was completed using copper free “click” synthesis in order to avoid copper
metal difficult purification and biological toxicity associated with trace metal
impurities in the final product.

Figure 4.1. Illustration of targeting ligand attachment to SMAPIE-PEI-N3 micelles
via strain promoted alkyne azide cycloaddition (SPAAC) “click” reaction.

The successful synthesis of SMAPIE-PEI-N3 product was confirmed by

FT/IR and 1H NMR spectroscopy. FT/IR spectra (figure 4.2) showed the absence
of the anhydride –C=O characteristic antisymmetric and symmetric stretch peaks
in SMAPIE-PEI-N3 at 1859 cm-1 and1776 cm-1 respectively with the appearance
of the secondary amide–C=O stretch at 1671 cm-1 indicating anhydride ring
opening in SMAPIE and formation of the amide bond linker between the two
polymeric chains. In addition, the azide –N3 stretch at 2105 cm-1 confirmed the
diazo-transfer reaction.
1H

NMR spectra (figure 4.3) further supported the SMAPIE-PEI-N3

copolymer synthesis. 1H NMR spectra of unreacted SMAPIE and PEI chains were
presented in figure 4.3.A and figure 4.3.B, respectively. 1H NMR spectrum of
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separately synthesized PEI-N3 (figure 4.3.C) illustrated the occurrence of partial
azido modification of PEI chain without any other side reactions. PEI protons on
carbons adjacent to unmodified amine groups (-CH2CH2NH-) were at chemical
shift 2.2-3 ppm, while the protons on carbons adjacent to azide groups (NHCH2CH2N3) and (-NHCH2CH2N3) were at chemical shift of 3 ppm and 3.3 ppm,
respectively. As shown in figure 4.3.D, 1H NMR spectrum of isolated SMAPIE-PEI
product of the one pot reaction first step indicated grafting of SMAPIE on PEI chain.
PEI (-CH2CH2NH-) characteristic peak at chemical shift 2.2-3 ppm, overlapping
peaks of (-COCH- and -OCH2- in SMAPIE copolymer, and -CH2NHCO- in PEI
chain) at 3.1-3.5 ppm, and the SMAPIE (C6H5-) peak in cumene terminal and
styrene residues at 6.4-7.4 ppm were obviously detected. 1H NMR spectrum of
SMAPIE-PEI-N3 (figure 4.3.E) showed the PEI (-CH2CH2NH-) characteristic peak
at chemical shift 2.2-3 ppm, overlapping peaks of (-COCH- and -OCH2- in SMAPIE
copolymer, -CH2NHCO- and -NHCH2CH2N3 in PEI chain) at 3.1-3.6 ppm, and the
SMAPIE (C6H5-) peak in cumene terminal and styrene residues at 6.4-7.4 ppm.
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Figure 4.2. FT/IR spectra of PEI polymer (green), SMAPIE copolymer (blue), and
SMAPIE-PEI-N3 micelles forming block copolymer (red).
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Figure 4.3. 1H NMR spectra of (A) SMAPIE in DMSO (B) PEI in D2O (C) PEI-N3
in D2O (D) SMAPIE-PEI in CD3OD (E) SMAPIE-PEI-N3 in CD3OD.
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4.1.2 Synthesis of Targeting Ligand Conjugated SMAPIE-PEI-Gal Micelles
Forming Block Copolymer
SMAPIE-PEI-Gal (galactosamine targeted micelles forming block co-

polymer) was synthesized using copper free “click” chemistry in essence to obtain
biocompatible micelles that can target ASGPR in hepatocellular carcinoma. During
the first step, galactosamine as a targeting ligand was linked via amide bond to
DBCO-PEG5 moiety by amine reactive NHS coupling chemistry. The presence of
PEG moiety in DBCO-PEG5-NHS ester helped to improve its water solubility and
hence its reactivity. Galactosamine was added in three fold excess compared to
DBCO-PEG5-NHS ester to ensure complete ester modification by the end of the
reaction. Galactosamino-PEG5-DBCO (targeting) blocks was then attached to
SMAPIE-PEI-N3 micelles using copper free “click” chemistry.
“Click” chemistry as a synthetic tool has been extensively studied in the
previous years and has several advantages including high selectivity, high reaction
yield, high efficiency, fast reaction rate, mild reaction conditions and water
compatibility108. “Click” chemistry, either copper catalyzed or copper free, has been
used in many applications including polymer synthesis140,141, and conjugation of
imaging agents or targeting ligands on nanosystems 142,143. Copper free
cycloaddition approach has also been used in liposomes functionalization 144, DNA
conjugation to nanoparticles145, and biorthogonal biomolecules labeling in living
cells both in vitro and in vivo146. One major advantage of the copper free approach
over the copper catalyzed one is the biocompatibility and absence of toxicity for
living cells since cyclooctyne ring strain is the primary reaction promotor instead of
the cytotoxic copper metal catalyst. Such reactions can thus be carried out without
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the need for purification or removal of copper and highly useful for biological
applications.
Successful synthesis of biocompatible SMAPIE-PEI-Gal was verified using
1H

NMR spectra as shown in figure 4.4. The unreacted galactosamine protons

characteristic peaks are illustrated in figure 4.4.A. 1H NMR spectrum of SMAPIEPEI-Gal co-polymer is presented in figure 4.4.B. In addition to the characteristic
peaks in SMAPIE-PEI-N3 mentioned above (figure 4.3.E), galactosamino-PEG 5DBCO attachment was confirmed by the presence of the following peaks: (-CHNH2
) protons in galactosamine alpha and beta anomers and (-OCH2CH2O-) in PEG
chain at 3-3.49 ppm, (-CHCHOH, -CH2OH, -CHCH2-) protons in galactosamine
alpha and beta anomers at 3.5-4 ppm, (-OCHOH alpha and beta anomeric
protons) in galactosamine at 4.5, 5 ppm, overlapping peaks of (-C6H4 in substituted
DBCO and -C6H5 in cumene terminal and styrene residues) at 6.4-7.6 ppm.
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Figure 4.4. 1H NMR spectra of (A) Galactosamine in D2O (B) SMAPIE-PEI-Gal in
D2O.
4.2 Size Exclusion Chromatography (SEC)

Size exclusion chromatography was run to detect the molecular weight of
the SMAPIE-PEI-N3 micelles relative to molecular weights of standards. Gel
filtration chromatography was chosen as the experimental method since SMAPIEPEI-N3 micelles are water soluble.
The chromatogram of SMAPIE-PEI-N3 micelles (figure 3.1) revealed
unimodal molecular weight distribution, indicating that the micelles were of uniform
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size with low polydispersity index. The relative molecular weight of micelles
obtained by substitution in the standard curve equation (figure 3.2) was 13474.58
Da. Although the molecular weight obtained is relative and not an absolute one, it
nonetheless gave a good estimation of the micelle composition. From the
molecular weight estimation, it can be concluded that only one chain of the 2.3
KDa SMAPIE copolymer got grafted to one chain of the 10 KDa PEI polymer in
addition to the molecular weight increase as a result of partial amine groups
modification to azide groups. This conclusion was in agreement with what was
expected based on the polymers composition and the equimolar ratio at which the
synthesis was performed. According to copolymer composition information
provided by the manufacturer, SMAPIE copolymer has a molar ratio of 4:1 of
styrene to anhydride units, and 75% of the anhydride rings are esterified. Molar
ratio calculations indicated that each SMAPIE copolymer chain contained
approximately 3 opened and 1 unopened anhydride rings. Thus, presence of only
1 unopened anhydride ring in each SMAPIE copolymer chain prevents the grafting
of more than one PEI polymer chain on the same SMAPIE copolymer chain, which
helped to reduce polydispersity and chances of crosslinking.
4.3 Copper Assay
PEI is a cationic polymer that has been well studied for condensing
negatively charged siRNAs. The role of PEI in both non-targeted SMAPIE-PEI-N3
and ASGP receptor targeted SMAPIE-PEI-Gal micelles is mainly for gene/siRNA
complexation. The exact content of PEI is essential for correct calculation of
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micelles amount necessary for micelleplexes formation at the desired amine
groups in polymer/phosphate groups in nucleic acids (N/P) ratio.
The PEI concentration in micelles forming block co-polymer was quantified
through spectrophotometry by copper chelate formation. According to pervious
reports, copper ions form specific blue cuprammonium complex with primary
amine groups in PEI polymer137.

The intensity of so-formed blue color is a

reflection of the PEI concentration as long as the conditions for beer-lambert laws
were followed. PEI chains in both SMAPIE-PEI-N3 and SMAPIE-PEI-Gal copolymers are the only regions containing primary amine groups, and hence
accurate quantification of PEI composition in both micelles can be done using
copper chelation, without any interference.
As shown in figure 3.3, PEI content in SMAPIE-PEI-Gal micelles was lower
than in SMAPIE-PEI-N3 micelles because of the extra galactosamino-PEG 5DBCO moieties in SMAPIE-PEI-Gal co-polymer. In line with the size exclusion
chromatography, copper assay results also confirmed that only one chain of
SMAPIE copolymer was grafted to one chain of PEI in SMAPIE-PEI-N3 and
SMAPIE-PEI-Gal co-polymers.
4.4 Determination of Critical Micelle Concentration (CMC)
The estimation of critical micelle concentration using pyrene as a
fluorescent hydrophobic probe, is a way to confirm the ability of amphiphilic
copolymers to form micelles. Amphiphilic copolymers are usually block copolymers composed of hydrophilic and hydrophobic moieties that self-assemble in
aqueous environment into micellar spherical core-shell structure, at concentration
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exceeding the critical micelle concentration 80. When CMC is reached in aqueous
environment, the hydrophobic moieties of the amphiphilic copolymer start to
associate with each other and away from water to reach more favorable entropy
forming the micellar core while the hydrophilic moieties form the micellar shell 82.
According to the SMAPIE copolymer composition information and based on
molar ratio calculations, each SMAPIE chain contained around 17 styrene groups,
3 opened and 1 unopened anhydride rings. The big number of the styrene
hydrophobic rings (17) together with the iso-octyl aliphatic chains esterified with
the open anhydride rings participated in creation of the hydrophobic core of the
SMAPIE-PEI-N3 micelles, while hydrophilic PEI polymeric chain formed the shell.
Pyrene is a fluorescent hydrophobic probe whose excitation wavelength
vary depending on the hydrophobicity of the surrounding environment, where it is
lower in a hydrophilic environment than in a hydrophobic one 147. Bathochromic
shift in pyrene excitation wave length from 334 nm to 339 nm with increasing
SMAPIE-PEI-N3 copolymer concentration indicated pyrene presence in the
hydrophobic core of the formed micelles when CMC was exceeded (figure 3.4).It
was reported that micelles of CMC in order of 10-6-10-7 M increase the blood
circulation time of their cargo as they have good stability in vivo 84. SMAPIE-PEIN3 micelles was formed at low concentration and CMC was in the 10 -7 M range
which indicates that SMAPIE-PEI-N3 micelles are good candidates for in vivo
drug/gene delivery and can have good stability profile for in vivo applications.
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4.5 SYBER Gold Assay
Optimal nucleic acids complexation ability is a prerequisite for non-viral
gene/siRNA vectors to achieve required gene/siRNA protection and effective
cellular transfection148. Polymeric vectors based nucleic acids complexation can
be evaluated using SYBER Gold assay.
SYBER Gold is a fluorescent dye that binds to both free and uncondensed
siRNA and emits fluorescence, the more the siRNA gets condensed and
sequestered in the micelleplexes or polyplexes the less the free siRNA available
to bind to the dye and the more its fluorescence quenching 149,150.
As shown in figure 3.6, the siRNA complexation capacity of all micelleplexes
and polyplexes increased with increasing the N/P ratio. The reason is that, nucleic
acids complexation with micelles or polymers occur through electrostatic
interaction between negatively charged phosphate groups in nucleic acids and
cationic groups in PEI polymeric units. As the N/P ratio increases, total cationic
charge increases which allow better ionic interaction and more efficient siRNA
condensation131. Non-targeted SMAPIE-PEI-N3 micelles showed lesser siRNA
complexation efficiency compared to PEI polymers. It may be attributed to the
presence of the negatively charged carboxylate groups in SMAPIE copolymer.
According to previous study, carboxylate anions can diminish the electrostatic
binding of nucleic acids to polycations138. Strikingly, galactosamino-PEG5 moieties
didn’t hinder or weaken the siRNA access and ionic interaction with PEI segments
in SMAPIE-PEI-Gal micelles, but instead, the targeted micelles showed
comparable siRNA condensation capacity to PEI polymers. It was previously
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reported that carbohydrates can form hydrogen bonding with nucleic acids and
increase their complexation efficiency in polyplexes 148.One possible explanation,
in line with previous report, is that galactosamine carbohydrate residues might
have an important role in improved SMAPIE-PEI-Gal micelles condensation ability
by formation of hydrogen bonding with siRNAs.
4.6 Size and Zeta Potential Measurements: Light Scattering (LS)
The amphiphilic nature of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal copolymers enabled them to self-assemble to form nanomicelles spontaneously in
aqueous solution. The micelles can condense siRNA forming micelleplexes. Both
particle size and surface charge (or zeta potential) are important aspects that affect
particles cytotoxicity, localization, cellular uptake and transfection efficiency 151,152.
Small particles achieve better cellular uptake, and moderate positive zeta potential
decreases particles aggregation and increases their colloidal stability without being
highly cytotoxic149,153.
Hydrodynamic sizes of plain micelles (without loaded siRNA) and siRNA
containing micelles (micelleplexes), and polyplexes were measured using dynamic
light scattering (DLS) technique, while their zeta potentials were determined by
electrophoretic light scattering (ELS). As shown in figure 3.7.A, hydrodynamic
diameter of SMAPIE-PEI-Gal micelles was found to be larger than that of SMAPIEPEI-N3 micelles, due to the presence of additional galactosamino-PEG 5 moieties.
Figure 3.7.B illustrated that, both SMAPIE-PEI-Gal and SMAPIE-PEI-N3 micelles
had high zeta potential of around 40 mV because of the cationic amino groups
present in the PEI chain. However, siRNA complexation with both micelles
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neutralized large portion of their cationic charge and hence decreased their
cytotoxicity. In figure 3.8, micelleplexes and polyplexes formed at lower N/P ratios
exhibited larger particle sizes as compared to the ones formed at higher N/P ratios,
till complete siRNA condensation is realized154, where a size of 200 nm is noted.
As presented in figure 3.9, all micelleplexes and polyplexes showed similar trend
of increasing zeta potential as N/P ratio increases, which is in line with previously
published reports132,143. Larger particle sizes as well as negative zeta potential
indicated inefficient and loose siRNA condensation 149. N/P ratio of 7 for SMAPIEPEI-N3 and 4 for SMAPIE-PEI-Gal micelleplexes, seemed to be the most optimal
N/P ratios, where the particles had the smaller size together with lesser positive
surface charge. Micelleplexes and polyplexes prepared at N/P ratio of 10 were
thus chosen for further experiments to allow data comparison.
As demonstrated in tables 3.1 and 3.2, micelles and micelleplexes with
efficient siRNA sequestering were of moderate size distribution with PDI ≤ 0.42.
However, higher PDI was obtained at improper siRNA complexation due to the
formation of loose aggregates with larger size.
4.7 Size and Morphology Measurements: Transmission Electron Microscopy
(TEM)
Size and morphology of plain micelles and micelleplexes were determined

in the dry state by transmission electron microscopy (TEM). Micelles and
micelleplexes presented spherical Core/Shell structure (figure 3.10) similar to
previously published results94,155. The core/shell structure presented further
confirmed the ability of the amphiphilic SMAPIE-PEI co-polymer to self-assemble
into micelles in aqueous environment, where the hydrophobic styrene rings and
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iso-octyl chains of SMAPIE arranged to form the white/unstained core 93 and the
hydrophilic amine groups of PEI occupied the outer shell with the dark stain. In line
with earlier publication, the styrene residues aromatic interaction contributed to the
formation of uniform and tightly packed dense micellar core that was more resistant
to water infiltration93.
SMAPIE-PEI-Gal micelles showed larger size ( ̴ 200 nm) than SMAPIE-PEIN3 micelles ( ̴ 100 nm) due to the excess molecular weight of galactosamino-PEG 5
moieties in SMAPIE-PEI-Gal micelles. In contrast, the SMAPIE-PEI-Gal
micelleplexes exhibited smaller size than SMAPIE-PEI-N3 micelleplexes, probably
due to more efficient packaging/condensation of siRNA in SMAPIE-PEI-Gal
micelleplexes than in SMAPIE-PEI-N3 micelleplexes.
In the case of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles and
micelleplexes, TEM sizes were of similar pattern with the ones obtained from DLS
measurements, however they were noted to be smaller in general. This was
explained by the state of micelles in which the size measurements were performed.
The results are in good agreement as the hydrodynamic sizes measured by DLS
are known to be larger than the dry state sizes measured by TEM.
4.8 Buffer Capacity Measurements
Drugs and nucleic acids have to evade lysosomal degradation in order to
go to their sites of action in the cell. In the case of siRNAs, the gene silencing
occurs in the cytoplasm and thus the siRNA has to be released in the cytoplasm
for necessary action. Buffering capacity is an important measure for polycationic
vectors that allows endosomal escape of the cargo. The buffering capacity is
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evaluated by the amount of protons necessary for reducing the pH in the
endosomal pH range of 7-5.5138.
PEI based cationic polymeric vectors have been shown to have optimal
buffering capacity as a result of having many protonatable amine groups in their
backbone156. According to the proton sponge hypothesis, amine groups in PEI get
protonated and increase osmotic pressure in endosomes leading to their
membrane rupture and release of drug/nucleic acids in cytoplasm 157.
Acid base titrations are perfect evaluators of the buffering capacity. Good
buffering capacity is indicated by slow, rather than steep change in pH, upon
addition of the same amount of HCl to polymeric solutions during titration 158.
As shown in figure 3.11, a sharp drop in pH was seen during acid titration
of 150 mM NaCl solution (the negative control), which had no buffering capacity.
On the other hand, all the positive control PEI polymers, as well as SMAPIE-PEIN3 and SMAPIE-PEI-Gal micelles exhibited small pH changes with acid addition
indicating their good buffering capacity. Two inflection points of slow pH changes
were seen in titration curves of the polymers and the micelles as a result of having
different types of protonatable amine residues (primary, secondary, and tertiary).
This was in agreement with previous reports159,160. SMAPIE-PEI-N3 micelles
showed lower buffer capacity compared to PEI because of the partial azide
modification in SMAPIE-PEI-N3 polyethylenimine segment, which decreased the
number of available protonatable amine groups. Another reason is that the
carboxylic acid groups in SMAPIE could protonate some PEI primary amines into
ammonium groups through zwitter-ion formation. According to a previous study,
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ammonium groups can suppress protonation of surrounding amine groups 161. On
the other hand, SMAPIE-PEI-Gal micelles were very similar to PEI polymers and
better than SMAPIE-PEI-N3 micelles in their buffering capacity. Triazole rings
conjugating galactosamino PEG5 moieties in SMAPIE-PEI-Gal micelles had amine
groups which participate in increasing the micelles buffering ability by being
protonatable at 7-5.5 pH range.
4.9 Biological evaluation of SMAPIE-PEI-N3 and SMAPEI-PEI-Gal micelles
4.9.1 Cytotoxicity Assay Using Human Liver Cancer Cells
Cytotoxicity is one of the most important aspects in the evaluation of nonviral gene/siRNA vectors composed of cationic polymers for safe gene therapy.
Cytotoxicity of non-targeted SMAPIE-PEI-N3, and targeted SMAPIE-PEI-Gal
micelles forming block co-polymers were investigated in Hep G2 cells. PEI
polymers were studied as controls for comparison.
As shown in figure 3.12, SMAPIE-PEI-Gal < PEI 10 KDa < SMAPIE-PEI-N3
< PEI 25 KDa in order of their cytotoxicity and IC50. PEI 25KDa was more cytotoxic
than PEI I0 KDa due to its higher cationic charge density, which interacts with the
cell membrane and causes cell necrosis139. In line with previously reported studies,
galactosamino-PEG5 moieties in SMAPIE-PEI-Gal micelles lead to reduction in
cytotoxicity by 2-fold as compared to PEI 10 KDa and by 3-fold as compared to
SMAPIE-PEI-N3 micelles due to possible shielding of cationic PEI groups 132,150.
Unexpectedly, SMAPIE-PEI-N3 was more cytotoxic than PEI 10 KDa, but this
might be explained by the conformation of the cationic groups in the shell of the
micelles that might arrange in a way that increased their electrostatic interaction
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with the negatively charged cell membrane and induced more toxicity. However,
addition of targeting ligand or other functional moieties to SMAPIE-PEI-N3 micelles
block copolymer can reduce its cytotoxicity as proven in case of SMAPIE-PEI-Gal
copolymer.
SMAPIE-PEI-N3 micelles, SMAPIE-PEI-Gal micelles, and PEI 10 KDa
polymer were complexed with siRNA to form less cytotoxic micelleplexes or
polyplexes used subsequently in cellular uptake or transfection evaluation
experiments. The reason for the lesser cytotoxicity is because the negatively
charged siRNA gets condensed by ionic interaction with a portion of the cationic
groups in the micelles or PEI 10 KDa polymer, thus decreasing the number of the
cationic groups available to interact with the cell membrane to cause
cytotoxicity131,162. Although, cell viability was more than 80% in case of SMAPIEPEI-N3, SMAPIE-PEI-Gal, and PEI 10 KDa at concentrations below 20 µg/mL, and
siRNA condensation should improve the cell viability more, it is important to note
that the polymers or micelles concentration used in the subsequent in vitro
experiments was 6.7 µg/mL or lesser depending on the micelle or polymer type.
As a result, more than 90% cell viability was ensured in all the following in-vitro
experiments.
4.9.2 Cellular Uptake Quantification by Flow Cytometry
Cellular uptake is an ultimate prerequisite for specific siRNA delivery and
achievement of good transfection efficiency. Naked siRNAs are degraded by
serum nucleases and have poor cell membrane penetration ability. These major
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obstacles of diminished stability and poor cellular uptake, ultimately result in
restricted and inefficient delivery71,163.
Polycationic vectors have shown promising potentials for resolving the
siRNA delivery problems. Polycationic vectors such as PEI can electrostatically
complex siRNA and sequester them from the enzymatic degradation by
endo/exonucleases. They also improve the siRNA cargo cellular delivery through
mediating endocytic cellular internalization 70. Polycationic vectors functionalized
with receptor specific targeting ligands help to achieve selective active targeting of
siRNA therapy to affected tissues that overexpress the complementary ligand
receptors and thus increase the therapeutic efficiency101,150,164.
Asialoglycoprotein (ASGP) receptors are among those targetable
receptors, and are used for targeted therapy of liver cancer. ASGPRs are c-type
lectin receptors165 that were found to be over expressed in several human
neoplastic hepatocytes118 and hepatocellular carcinoma cell lines including Hep
G2 and Huh7.5 cells119,120. ASGPRs selectively binds and internalize different
molecules

terminating

galactosamine,

or

N-

with

carbohydrate

acetylgalactosamine

residues
through

such

as

receptor

galactose,
mediated

endocytosis121,122.
Cellular uptake quantification and analysis using flow cytometry was
conducted to evaluate the siRNA delivery ability as well as (ASGP) receptor
targeting efficiency of galactosamine targeted SMAPIE-PEI-Gal micelleplexes
versus the non-targeted SMAPIE-PEI-N3 ones in Hep G2 cells. PEI 10 KDa
polyplexes were studied as positive transfection control for comparison, while free
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siRNA and untreated cells served as negative controls. Micelleplexes or
polyplexes were formed by complexation of fluorescent FAM-siRNA with SMAPIEPEI-Gal, SMAPIE-PEI-N3 polycationic micelles and PEI 10 KDa polycationic
polymer.
As illustrated in figure 3.14, statistical analysis of the median fluorescence
intensities showed that naked siRNA achieved insignificant cellular uptake
compared to untreated cells. This could be attributed to poor stability and inefficient
cell penetration of the naked siRNA as mentioned above. On the other hand,
siRNA condensation with both polycationic micelles and PEI polymer protected the
siRNA and increased its cellular internalization significantly. Interestingly, cellular
uptake of non-targeted SMAPIE-PEI-N3 micelleplexes was not significantly
different from that of PEI 10 KDa polyplexes. One possible explanation is that,
SMAPIE-PEI-N3 micelleplexes which had PEI chain residues in their micellar
corona that were not decorated with targeting ligands, entered the cells via the
same endocytic pathway as PEI 10 KDa polyplexes. It was previously reported that
PEI polyplexes were taken up by Hep G2 cells through clathrin-mediated
endocytosis166. On the other hand, galactosamine targeted SMAPIE-PEI-Gal
micelleplexes showed 0.84 fold higher cellular entry than the non-targeted
counterparts. In line with earlier studies, SMAPIE-PEI-Gal micelleplexes where
taken up by Hep G2 cells through receptor mediated endocytosis, since the
galactosamine targeting ligands bind to the overexpressed ASGPRs facilitating the
micelleplexes cellular internalization selectively in huge quantities 124,125. This
pathway was further confirmed by the significant decrease in the cellular uptake of
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SMAPIE-PEI-Gal micelleplexes in the presence of free galactosamine as
competitive control. The free galactosamine didn’t prevent SMAPIE-PEI-Gal
micelleplexes internalization completely since it only competed for the ASGP
receptors (without irreversibly occupying them) thereby decreasing their timely
availability for SMAPIE-PEI-Gal micelleplexes. The enhanced ASGPRs targeting
efficiency of SMAPIE-PEI-Gal micelleplexes suggests its potential value for
selectively targeting hepatocytes for treatment of hepatocellular carcinoma and
other liver diseases that overexpress the target receptors (ASGPRs).
4.9.3 Cellular Uptake and Endosomal Escape by Confocal Laser Scanning
Microscopy (CLSM)
Confocal laser scanning microscopy serves as an important tool for

visualization, imaging and studying of drugs / nucleic acids nanocarriers cellular
uptake as well as their sub-cellular localization. The process involves the use of
fluorescent labels for marking the carriers or their cargo and also for
denoting/marking the necessary cellular compartments.
Confocal laser scanning microscopy was performed to study the ability of
both targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEI-N3 micelleplexes
to deliver siRNA to cytoplasm of asialoglycoprotein receptor (ASGPR) positive Hep
G2 cells as well as the route of cellular uptake. PEI 10 KDa polyplexes were used
as positive control. ASGPR targeting efficiency of SMAPIE-PEI-Gal micelleplexes
was evaluated in absence and presence of free galactosamine as competitor
ligand of ASGPRs.
Micelleplexes or polyplexes were prepared with FAM-labeled siRNA at N/P
ratio of 10. The cells nuclei were stained with Hoechst 33342 stain (blue), acidic
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endosomal compartments with Lyso Tracker Deep Red dye (red), and siRNA was
labeled with FAM (green).
As shown in figure 3.15, the sub-cellular localization of the green fluorescent
siRNA was in the cytoplasm around the blue nucleus or in the red endosomal
compartments at 22 hours post transfection. The co-localization of siRNA (green)
and endosomes (red) as denoted by yellow colored regions in the merged images
indicated that the siRNA complexes underwent cell entry through endocytosis.
SMAPIE-PEI-N3 micelleplexes and PEI 10 KDa polyplexes most likely entered
through non-specific endocytosis due to electrostatic interaction of their cationic
charge with the anionic plasma membrane as noted before71. On the other hand,
and in concordance with the flow cytometry results, galactosamine targeted
SMAPIE-PEI-Gal micelleplexes were taken up into Hep G2 cells that overexpress
ASGPRs primarily via receptor mediated endocytosis. Indeed, the galactosamine
ASGPRs targeting effect in SMAPIE-PEI-Gal micelleplexes was proven by the
huge reduction in the micelleplexes uptake with free galactosamine competitor
presence in the transfection medium as reflected by the lowering of green
fluorescence intensity (figures 3.15 and 3.16).
As illustrated in the CLSM images, most of the green siRNA spots were
present in the cytoplasm compared to very little amount remaining entrapped in
the endosomes. This was true in the case of targeted SMAPIE-PEI-Gal
micelleplexes and PEI 10 KDa polyplexes, while for the non-targeted SMAPIEPEI-N3 micelleplexes, more portion of the siRNA remained in the endosomes
compared to that released in the cytoplasm at the same time point. This result
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could be attributed to the previously found low buffering capacity of SMAPIE-PEIN3 micelles versus SMAPIE-PEI-Gal micelles and PEI 10 KDa polymer (figure
3.11). In line with previous findings70,132,167, the high buffering ability of SMAPIEPEI-Gal micelleplexes and PEI 10KDa polyplexes increased their endosomal
escape, which consequently increased the available siRNA for gene silencing
through binding to the RNA induced silencing complex (RISC) in the cytoplasm
causing the required RNA interference. This suggests that SMAPIE-PEI-Gal
micelleplexes could achieve better transfection efficiency and specific gene
knockdown than the non-targeted SMAPIE-PEI-N3 micelleplexes.
4.9.4 Transfection Efficiency and Nrf2 Gene Knockdown by Western Blot
analysis

SMAPIE-PEI-Gal micelleplexes transfection efficiency and ability to deliver

siRNA to Hep G2 cells in an effective manner was evaluated using western blot
analysis. Effective siRNA delivery is a prerequisite for achieving efficient gene
knockdown, which is the ultimate goal of siRNA therapy.
Nrf2 gene was chosen as target gene for the study due to its established
role

in

promoting

chemoresistance,

as

HCC

cells

proliferation,

documented

in

invasion,

previous

metastasis,

and

publications49,57,58.

Nrf2

downregulation or inhibition was proven to resensitize HCC cells to many
anticancer drugs including 5-fluorouracil (5-FU), cisplatin, and doxorubicin 57–59. As
a result, Nrf2 protein is a potential therapeutic target in HCC management.
SMAPIE-PEI-Gal micelleplexes and PEI 10 KDa polyplexes were prepared
by complexing Nrf2-siRNA or negative control non-target specific siRNA (NCrsiRNA) at N/P ratio of 10. PEI 10 KDa was used as positive transfection control,
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while micelleplexes or polyplexes condensing NCr-siRNA were used as negative
controls for comparison. Hep G2 cells were chosen for the study as it was reported
to be positive for Nrf2 expression with Nrf2 main localization in the cytoplasm 168.
Hep G2 cells were transfected for 24 hours with micelleplexes or polyplexes
containing 50 nM siRNA through reverse transfection technique as Hep G2 cells
are among the “hard to transfect” cell lines169 and reverse transfection was
reported to achieve superior results as compared to the traditional transfection
methodology. The Nrf2 protein half-life was reported to be very short (less than 20
minutes)170, consequently similar to previous publication, the transfection time in
the study was set to 24 hours after which immunoblotting was performed for Nrf2
protein level measurement and gene knockdown assessment 171.
As demonstrated from the results (figure 3.17), after 24 hours of
transfection, both Nrf2 condensing SMAPIE-PEI-Gal micelleplexes and PEI 10
KDa polyplexes succeeded to achieve statistically significant (p ˂ 0.05) Nrf2 gene
knockdown and Nrf2 protein translation interference by around 49% and 27%
respectively. In line with previously obtained cellular uptake, buffering capacity and
endosomal escape data, these results confirmed the ability of SMAPIE-PEI-Gal
micelles to effectively deliver siRNA in HCC cells in effective quantity, with effective
endosomal escape and high availability for incorporation in the cytoplasmic
silencing machinery in order to produce efficient gene knockdown. Interestingly,
SMAPIE-PEI-Gal micelleplexes exhibited statistically significant and superior Nrf2
gene knockdown when compared with that observed with PEI 10 KDa polyplexes,
(p ˂ 0.05). This could be explained by the efficient ASGPRs based internalization
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and targeting ability and the higher cellular uptake of SMAPIE-PEI-Gal
micelleplexes than PEI 10 KDa polyplexes as illustrated before. In conclusion,
SMAPIE-PEI-Gal micelles forming block copolymer is a promising vector for
delivering Nrf2 siRNA, promoting sequence specific gene knockdown in Hep G2
liver cancer cells. The newly synthesized micelle forming block co-polymer thus
holds potential to serve as targeted nanocarrier delivery system to counteract the
chemoresistance of HCCs.
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SUMMARY
In this study, we successfully synthesized micellar polymeric nanodelivery
system that can be used as multifunctional modular platform in cancer therapy
and/or diagnosis. The micelles (SMAPIE-PEI-N3) were constructed from
poly(Styrene-co-maleic anhydride, partial iso-octyl ester) co-polymeric chain
(SMAPIE) grafted to branched polyethylenimine10 KDa polymeric chain (PEI) in
which primary amine groups were partially modified into azide groups (N3).
Different targeting ligands and imaging agents can be conjugated to SMAPIE-PEIN3 micelles simultaneously or individually by applying copper free “click” chemistry
strategies, for targeting various resistant and metastatic cancers overexpressing
complementary receptors. In this study, as a proof-of-concept, galactosamine
decorated micelles (SMAPIE-PEI-Gal) were synthesized to efficiently target
asialoglycoprotein (ASGP) receptors overexpressed in liver cancers.
The successful synthesis of targeted and non-targeted micelles forming
block copolymers was confirmed by 1H NMR and FT/IR. The relative molecular
weight and PEI composition of the micelles were determined using size exclusion
chromatography and copper chelation assay, respectively. Critical micelle
concentration of SMAPIE-PEI-N3 micelles was determined using pyrene as a
fluorescent probe and was found to be as low as 0.0112 mg/ml, indicating its
potential to be of high stability even on dilution in vivo. In terms of the siRNA
condensation ability evaluated by the SYBER Gold fluorescent dye, SMAPIE-PEIGal micelles were found to be of more efficient siRNA condensation capacity than
SMAPIE-PEI-N3 micelles at N/P ratio lower than 10. The hydrodynamic size of
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SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles was around 160 nm and 240 nm
respectively with moderate polydispersity index, but they had high zeta potential
of about 40 mV. On the other hand, SMAPIE-PEI-N3 and SMAPIE-PEI-Gal
micelleplexes exhibited decreasing pattern of hydrodynamic size with increasing
N/P ratio and achieved more complete siRNA condensation. The size of 200 nm
at N/P ratio of 10 is optimum for EPR mediated passive accumulation in cancer
tissues. SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelleplexes zeta potential
decreased as a consequence of siRNA condensation as compared to the highly
cationic plain micelles. Transmission electron microscopy (TEM) images
demonstrated the spherical core/shell morphology of both the plain micelles and
the siRNA complexing micelleplexes. In terms of buffering capacity and endosomal
escape potential, SMAPIE-PEI-Gal micelles were of high buffer capacity
comparable to that of PEI polymers. However it was found that SMAPIE-PEI-Gal
was superior to SMAPIE-PEI-N3 micelles in buffering ability. Cytotoxicity
evaluation of both targeted and non-targeted micelles in Hep G2 cells showed
more than 80% cell viability at concentrations below 20 µg/ml, however much
better cell viability was observed in the transfection experiments as only a total
polymer concentration of 6.7 µg/ml or lesser was used/needed.
Cellular uptake of SMAPIE-PEI-Gal micelleplexes via the ASGP receptor
mediated endocytosis was confirmed by the free galactosamine competition assay
results. In contrast to galactosamine targeted SMAPIE-PEI-Gal micelleplexes,
cellular uptake of non-targeted SMAPIE-PEI-N3 micelleplexes and PEI polyplexes
could be attributed to the cationic charge mediated non-specific endocytosis
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demonstrated in the co-localization of some SMAPIE-PEI-N3 micelleplexes and
PEI polyplexes with endosomes, as illustrated by CLSM. Quantification of cellular
uptake of PEI 10 KDa polyplexes, SMAPIE-PEI-N3 micelleplexes, and SMAPIEPEI-Gal micelleplexes in Hep G2 cells by flow cytometry showed statistically
significant and superior cellular internalization by SMAPIE-PEI-Gal micelleplexes,
(p ˂ 0.01). Indeed, SMAPIE-PEI-Gal micelleplexes cellular uptake was higher than
that of SMAPIE-PEI-N3 micelleplexes and PEI 10 KDa polyplexes by 0.84 and 1.2
folds respectively, due to the overexpression of ASGPRs in HCC cells.
In conclusion, as noted from all the above data, SMAPIE-PEI-Gal micelles
forming block copolymer showed better physical and biological characteristics than
SMAPIE-PEI-N3 copolymer. As a result, SMAPIE-PEI-Gal micelles were chosen
to further study their siRNA transfection efficiency and ability to achieve effective
gene knockdown. As expected, SMAPIE-PEI-Gal micelleplexes successfully
mediated significant 0.49 fold Nrf2 gene knockdown in ASGPRs overexpressing
Hep G2 cells. The Nrf2 gene knockdown was 21% higher than the one mediated
by the positive transfection control PEI 10 KDa polyplexes at statistical significance
of (p ˂ 0.05). These results emphasize that SMAPIE-PEI-Gal is a promising
candidate for siRNA delivery to HCC. Its application to knockdown Nrf2 gene, can
counteract the “dark side” of Nrf2 in HCC, where it decreases HCC cells survival
and chemoresistance, warranting further investigations.
In future experiments, SMAPIE-PEI-Gal micelles can be studied both in vitro
and in vivo for co-delivery of chemotherapeutic agent and Nrf2 or MDR1 siRNA to
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overcome chemoresistance and achieve synergistic control on tumor growth in
HCC.
The scope of study could be extended by employing SMAPIE-PEI-N3 as a
modular micellar block co-polymer through attachment of different targeting
ligands or imaging agents and studying the potential of the so-formed
micelles/micelleplexes to achieve targeted therapy of different types of cancer.
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ABSTRACT
TARGETED DELIVERY OF NRF2 SIRNA USING MODULAR POLYMERIC
MICELLAR NANODELIVERY SYSTEM FOR EFFICIENT TARGET GENE
KNOCKDOWN IN HEPATOCELLULAR CARCINOMA
by
SHAIMAA YOUSEF
August 2016
Advisor: Dr. Arun Iyer
Major: Pharmaceutical Sciences (Pharmaceutics)
Degree: Master of Sciences
Tumor selective drug delivery as well as chemotherapy associated multi
drug resistance (MDR) pose tremendous hurdles for effective cancer therapy. In
this regard, designing multifunctional nanocarriers loaded with drug/gene payloads
and engineered with tumor targeting ligands can serve as a modular platform for
targeted drug/gene delivery. In this study we undertook the synthesis of a selfassembling block copolymer constructed using poly(styrene-co-maleic anhydride,
partial iso-octyl ester) (SMAPIE) and branched polyethylenimine (PEI) as building
blocks and evaluated its micelle forming ability, siRNA complexation and siRNA
delivery potentials. In addition, we engineered galactosamine decorated
nanomicelles using modular “click” chemistry based approaches for evaluating the
targeted delivery of Nrf2 siRNA to Hep G2 liver cancer cells overexpressing
asialoglycoprotein receptors (ASGPRs). Our results demonstrate that the
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galactosamine decorated nanocarriers could effectively deliver Nrf2 siRNA into
Hep G2 liver cancer cells resulting in efficient target gene knockdown, evincing its
potential for targeted liver cancer therapy.
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